[
  {
    "id": "tds-1",
    "name": "FoundationOne CDx",
    "vendor": "Foundation Medicine",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS of FFPE tumor tissue; detects SNVs, indels, CNAs, and select rearrangements in 324 genes; reports MSI, TMB, and HRD signature.",
    "methodCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "genesAnalyzed": 324,
    "genesAnalyzedCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "geneListUrl": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Rearrangements", "TMB", "MSI", "HRD"],
    "biomarkersReportedCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "targetPopulation": "Patients with advanced solid malignant neoplasms requiring genomic profiling to guide treatment decisions",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf",
    "fdaStatus": "FDA-approved PMA (P170019) - First FDA-approved broad companion diagnostic for solid tumors",
    "fdaStatusCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-f1cdx-p170019s048",
    "fdaApprovalDate": "2017-11-30",
    "fdaApprovalDateCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf",
    "fdaCompanionDxCount": 57,
    "fdaCompanionDxCountNotes": "57 FDA-approved CDx indications in US as of Dec 2025 (100 total CDx indications including Japan). Includes pan-tumor indications for TMB-H, MSI-H, NTRK fusions, RET fusions, and tumor-specific indications across NSCLC, melanoma, breast, colorectal, ovarian, prostate, cholangiocarcinoma, and pediatric brain tumors.",
    "fdaCompanionDxCountCitations": "https://www.businesswire.com/news/home/20251204680697/en/Foundation-Medicine-Achieves-Historic-Milestone-of-100-Approved-and-Active-Companion-Diagnostic-Indications-Solidifying-Leadership-in-Precision-Medicine",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer", "Melanoma", "Gastric Cancer", "Cholangiocarcinoma"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers and 'broad molecular profiling' but do not endorse specific commercial assays by name.",
    "tat": "8 days",
    "tatNotes": "Typically 8 days or less from receipt of specimen.",
    "tatCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "sampleRequirements": "FFPE tissue; minimum 25% tumor content; 10 unstained slides or tissue block",
    "sampleRequirementsNotes": "Foundation Medicine contacts pathology lab for specimen procurement. Can reflex to FoundationOne Liquid CDx if tissue insufficient.",
    "sampleRequirementsCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "reimbursement": "Medicare",
    "reimbursementNote": "National Medicare coverage for advanced cancer (CAG-00450R). 87% of patients pay $0 out-of-pocket. 80+ commercial health plans cover Foundation Medicine tests.",
    "reimbursementCitations": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance | https://www.foundationmedicine.com/test/foundationone-cdx",
    "listPrice": 3500,
    "listPriceCitations": "https://www.foundationmedicine.com/faq/patient-faqs",
    "cptCodes": "0037U",
    "cptCodesCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "availableRegions": ["US", "EU", "UK", "Japan", "Canada", "Australia", "International"],
    "availableRegionsNotes": "Available in 100+ countries via Roche global network. US lab (Cambridge, MA) and EU lab (Penzberg, Germany). Regulatory: FDA approved (US), MHLW approved (Japan, Dec 2018), CE marked (EU).",
    "availableRegionsCitations": "https://www.roche.com/media/releases/med-cor-2021-10-25 | https://www.foundationmedicine.com/press-releases/aa55275f-b849-4e31-a770-152c8e7cad8f",
    "clinicalAvailability": "Commercially available in US since 2017; available in 100+ countries via Roche affiliates",
    "clinicalAvailabilityCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "numPublications": 1000,
    "numPublicationsPlus": true,
    "numPublicationsSource": "vendor-estimate",
    "numPublicationsNotes": "Foundation Medicine tests cited in >1,000 peer-reviewed publications (vendor estimate).",
    "numPublicationsCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "publicationsExampleCitations": ["https://doi.org/10.1038/nm.4333", "https://doi.org/10.1200/JCO.2017.75.3780"]
  },
  {
    "id": "tds-2",
    "name": "FoundationOne Liquid CDx",
    "vendor": "Foundation Medicine",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "approach": "Liquid CGP",
    "method": "Hybrid-capture NGS of cfDNA from plasma; analyzes 324 genes; reports short variants in 311 genes, rearrangements in 8 genes, CNAs in 3 genes, plus bTMB and MSI.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",
    "genesAnalyzed": 324,
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "genesReported": 311,
    "genesReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",
    "geneListUrl": "https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "biomarkersReported": ["SNVs", "Indels", "Select CNAs", "Select Rearrangements", "bTMB", "MSI"],
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "targetPopulation": "Patients with advanced solid tumors when tissue biopsy is not feasible or as complement to tissue testing",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",
    "fdaStatus": "FDA-approved PMA (P200006) August 2020",
    "fdaStatusCitations": "https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",
    "fdaApprovalDate": "2020-08-26",
    "fdaApprovalDateCitations": "https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",
    "fdaCompanionDxCount": 10,
    "fdaCompanionDxCountNotes": "Multiple CDx indications in NSCLC (osimertinib, sotorasib, capmatinib), breast cancer (PIK3CA), prostate cancer (BRCA1/2, ATM), cholangiocarcinoma (FGFR2), pan-tumor (NTRK).",
    "fdaCompanionDxCountCitations": "https://www.foundationmedicine.com/press-release/fda-approves-foundationonercdx-and-foundationonerliquid-cdx-companion-diagnostics",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Prostate Cancer", "Cholangiocarcinoma"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "7-10 days",
    "tatNotes": "Results typically available within 7-10 business days.",
    "tatCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "sampleRequirements": "2 tubes of whole blood in Streck cfDNA BCT tubes; minimum 5 mL per tube",
    "sampleRequirementsNotes": "7-day sample stability at ambient temperature. Can reflex to tissue testing if liquid negative for CDx mutations.",
    "sampleRequirementsCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "reimbursement": "Medicare",
    "reimbursementNote": "National Medicare coverage for advanced cancer. Broad commercial payer coverage.",
    "reimbursementCitations": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance",
    "listPrice": 3500,
    "listPriceCitations": "https://www.foundationmedicine.com/faq/patient-faqs",
    "cptCodes": "0239U",
    "cptCodesCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "availableRegions": ["US", "EU", "UK", "Japan", "Canada", "Australia", "International"],
    "availableRegionsNotes": "Available in 100+ countries via Roche global network. US lab (Cambridge, MA) and EU lab (Penzberg, Germany).",
    "availableRegionsCitations": "https://www.roche.com/media/releases/med-cor-2021-10-25",
    "clinicalAvailability": "Commercially available in US since 2020; available in 100+ countries via Roche affiliates",
    "clinicalAvailabilityCitations": "https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",
    "numPublications": 50,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Validation study PLoS One 2020 (Woodhouse et al.); multiple clinical validity studies for BRAF, HER2, MSI companion diagnostics",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/32976510/"
  },
  {
    "id": "tds-3",
    "name": "FoundationOne Heme",
    "vendor": "Foundation Medicine",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue/Blood/Bone Marrow",
    "approach": "Tissue + Liquid CGP",
    "method": "Hybrid-capture DNA sequencing of 406 genes plus RNA sequencing of 265 genes for fusion detection; covers hematologic malignancies and sarcomas.",
    "methodCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "genesAnalyzed": 406,
    "genesAnalyzedCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "rnaGenesAnalyzed": 265,
    "rnaGenesAnalyzedCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "geneListUrl": "https://www.foundationmedicine.com/test/foundationone-heme",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Rearrangements/Fusions", "TMB", "MSI"],
    "biomarkersReportedCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "cancerTypes": ["Hematologic malignancies", "Sarcomas"],
    "cancerTypesNotes": "Leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and sarcomas.",
    "cancerTypesCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "targetPopulation": "Patients with hematologic malignancies or sarcomas requiring comprehensive genomic profiling",
    "targetPopulationCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.foundationmedicine.com/test/foundationone-heme",
    "vendorNCCNAlignmentIndications": ["Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "B-Cell Lymphomas", "Myelodysplastic Syndromes", "Soft Tissue Sarcoma"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines for hematologic malignancies and sarcomas. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "10-14 days",
    "tatCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "sampleRequirements": "FFPE tissue, bone marrow aspirate, or peripheral blood depending on disease type",
    "sampleRequirementsCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage for qualifying patients. Commercial coverage varies.",
    "reimbursementCitations": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance",
    "listPrice": 3500,
    "listPriceCitations": "https://www.foundationmedicine.com/faq/patient-faqs",
    "availableRegions": ["US", "EU", "UK", "Japan", "Canada", "Australia", "International"],
    "availableRegionsNotes": "Available in 100+ countries via Roche global network.",
    "availableRegionsCitations": "https://www.roche.com/media/releases/med-cor-2021-10-25",
    "clinicalAvailability": "Commercially available in US; available internationally via Roche affiliates",
    "clinicalAvailabilityCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "numPublications": 100,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Validation study Blood 2016 (He et al.); 10+ studies at ASH 2013; part of Foundation Medicine ecosystem",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/27002118/"
  },
  {
    "id": "tds-4",
    "name": "Guardant360 CDx",
    "vendor": "Guardant Health",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "approach": "Liquid CGP",
    "method": "Digital sequencing of cfDNA; targets 74 genes; reports SNVs, indels, CNAs (6 genes), and fusions (4 genes) with high sensitivity at low allele frequencies.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "genesAnalyzed": 74,
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "genesReported": 55,
    "genesReportedNotes": "74 genes targeted, 55 genes with reportable short variants.",
    "genesReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "geneListUrl": "https://www.guardantcomplete.com/hcp/solutions/guardant360-cdx",
    "biomarkersReported": ["SNVs", "Indels", "Select CNAs", "Select Fusions"],
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "targetPopulation": "Patients with advanced solid tumors; first liquid biopsy with FDA-approved CGP indication for all solid tumors",
    "targetPopulationCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "fdaStatus": "FDA-approved PMA (P200010) August 2020 - First FDA-approved liquid biopsy NGS CDx",
    "fdaStatusCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s008 | https://www.targetedonc.com/view/fda-approves-guardant360-cdx-for-tumor-mutation-profiling-of-all-solid-cancers",
    "fdaApprovalDate": "2020-08-07",
    "fdaApprovalDateCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s008",
    "fdaCompanionDxCount": 6,
    "fdaCompanionDxCountNotes": "6 CDx indications: NSCLC (osimertinib/EGFR, amivantamab/EGFR exon 20, trastuzumab deruxtecan/ERBB2, sotorasib/KRAS G12C); Breast cancer (elacestrant/ESR1, imlunestrant/ESR1).",
    "fdaCompanionDxCountCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer/default.aspx | https://www.onclive.com/view/fda-clears-guardant360-cdx-as-companion-diagnostic-for-imlunestrant-in-esr1-mutated-breast-cancer",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://guardanthealth.com/guardant360-cdx/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer"],
    "vendorNCCNAlignmentNotes": "Covers all genes recommended by NCCN for NSCLC and relevant biomarkers for breast cancer treatment. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "5-7 days",
    "tatNotes": "Actionable results typically within 7 days; as fast as 5 days.",
    "tatCitations": "https://www.onclive.com/view/fda-clears-guardant360-cdx-as-companion-diagnostic-for-imlunestrant-in-esr1-mutated-breast-cancer",
    "sampleRequirements": "2 tubes of whole blood in Streck cfDNA BCT tubes; minimum 5 mL",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S008C.pdf",
    "reimbursement": "Medicare",
    "reimbursementNote": "Broadly covered by Medicare and commercial insurers representing >300 million lives.",
    "reimbursementCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer/default.aspx",
    "cptCodes": "0242U",
    "codeType": "PLA",
    "medicareRate": 5000,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "clinicalAvailability": "Commercially available in US since 2020",
    "clinicalAvailabilityCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "numPublications": 150,
    "numPublicationsPlus": true,
    "numPublicationsSource": "vendor-estimate",
    "numPublicationsNotes": "Guardant360 cited in >150 peer-reviewed publications (vendor estimate).",
    "numPublicationsCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "publicationsExampleCitations": ["https://pubmed.ncbi.nlm.nih.gov/33619370/", "https://pubmed.ncbi.nlm.nih.gov/37256839/"]
  },
  {
    "id": "tds-17",
    "name": "Guardant360 Liquid",
    "vendor": "Guardant Health",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeCount": 2,
    "approach": "Liquid CGP",
    "method": "Digital sequencing of cfDNA on Guardant Infinity platform; targets 744 genes; reports SNVs, indels, CNAs, CNLs, fusions/rearrangements, MSI, TMB, tumor fraction, and promoter methylation (epigenomic features). CHIP filtering via proprietary algorithm. Virus detection (EBV, HPV).",
    "methodCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "genesAnalyzed": 744,
    "genesAnalyzedCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "genesReported": 744,
    "genesReportedNotes": "Full 744-gene panel reported. 10x more genes than previous Guardant360 version and 10x higher sensitivity for tumor fraction quantification.",
    "genesReportedCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",
    "geneListUrl": "https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "CNLs", "Fusions/Rearrangements", "MSI", "TMB", "Tumor Fraction", "Promoter Methylation"],
    "biomarkersReportedNotes": "First and only liquid biopsy to deliver genomic and epigenomic insights (promoter methylation) from a single input. CHIP variants flagged via proprietary algorithm.",
    "biomarkersReportedCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",
    "targetPopulation": "Patients with advanced solid tumors; comprehensive genomic and epigenomic profiling for treatment selection",
    "targetPopulationCitations": "https://guardanthealth.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/",
    "fdaStatus": "CLIA LDT; not FDA-cleared/approved",
    "fdaStatusNotes": "Developed as a Laboratory Developed Test (LDT) by Guardant Health Clinical Laboratory (CLIA-certified). Distinct from Guardant360 CDx which is FDA-approved but covers only 74 genes.",
    "fdaStatusCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "fdaCompanionDxCount": 0,
    "fdaCompanionDxCountNotes": "LDT version - no FDA companion diagnostic claims. For FDA-approved CDx, see Guardant360 CDx.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://guardanthealth.com/guardant360/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer", "Melanoma"],
    "vendorNCCNAlignmentNotes": "Covers all guideline-recommended genomic biomarkers across advanced solid tumors plus emerging biomarkers. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "7 days",
    "tatNotes": "Median 7 days from sample receipt to results.",
    "tatCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "sampleRequirements": "Two 10 mL tubes of whole blood; ship same or next day at room temperature (do not freeze/refrigerate)",
    "sampleRequirementsCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "lod": "SNVs: 0.20% VAF; Indels: 0.26%; CNAs: 2.46 copies; Fusions: 0.05%; MSI: 0.05%; Tumor Fraction: 1.6%",
    "lodNotes": "LoD defined as allele fraction/copy number at 95% probability of detection for oncogenic variants. TMB evaluable at ≥0.3% sample allele fraction.",
    "lodCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "specificity": "≥99.9% for SNVs, Indels, CNAs, CNLs, Fusions, MSI, Promoter Methylation",
    "specificityCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "reimbursement": "Medicare",
    "reimbursementNote": "Covered by Medicare and major private payers for comprehensive genomic profiling of all advanced solid tumors.",
    "reimbursementCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",
    "availableRegions": ["US"],
    "availableRegionsNotes": "US availability via Guardant Health. International availability via regional spec sheets (AMEA region).",
    "availableRegionsCitations": "https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",
    "clinicalAvailability": "Commercially available in US; 2024 major upgrade launched",
    "clinicalAvailabilityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",
    "numPublications": 100,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Same platform as Guardant360 CDx; extensive clinical validation and companion diagnostic studies across multiple cancer types",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/34838325/"
  },
  {
    "id": "tds-5",
    "name": "Tempus xT CDx",
    "vendor": "Tempus AI",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Tumor-normal matched NGS of FFPE tissue and matched normal blood/saliva; detects SNVs, MNVs, indels in 648 genes plus MSI status; tumor-normal matching improves somatic variant accuracy.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf | https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "genesAnalyzed": 648,
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/ | https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test",
    "geneListUrl": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "biomarkersReported": ["SNVs", "MNVs", "Indels", "CNVs", "Rearrangements", "TMB", "MSI"],
    "biomarkersReportedNotes": "HRD and HLA genotyping available as add-ons via professional services report.",
    "biomarkersReportedCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",
    "targetPopulation": "Patients with previously diagnosed solid malignant neoplasms",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",
    "fdaStatus": "FDA-approved IVD (P210011) - National launch January 2025",
    "fdaStatusCitations": "https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test | https://investors.tempus.com/news-releases/news-release-details/tempus-announces-national-launch-fda-approved-xt-cdx-test",
    "fdaApprovalDate": "2024-06-01",
    "fdaApprovalDateCitations": "https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",
    "fdaCompanionDxCount": 2,
    "fdaCompanionDxCountNotes": "CDx claims for colorectal cancer (KRAS, NRAS, BRAF); positioned as one of the largest FDA-approved gene panels.",
    "fdaCompanionDxCountCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.tempus.com/oncology/genomic-profiling/xt/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Colorectal Cancer", "Breast Cancer", "Melanoma", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "14 days",
    "tatNotes": "Results typically within 14 days.",
    "tatCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "sampleRequirements": "FFPE tissue plus matched normal (blood or saliva)",
    "sampleRequirementsNotes": "Tumor-normal matched approach differentiates somatic from germline variants.",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",
    "reimbursement": "Medicare",
    "reimbursementNote": "CMS Advanced Diagnostic Laboratory Test (ADLT) designation; Medicare rate $4,500.",
    "reimbursementCitations": "https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",
    "listPrice": 4500,
    "listPriceCitations": "https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",
    "cptCodes": "0473U",
    "cptCodesCitations": "https://www.discoveriesinhealthpolicy.com/2024/09/cms-releases-preliminary-crosswalk-for.html",
    "codeType": "PLA",
    "medicareRate": 4500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "clinicalAvailability": "Commercially available nationwide since January 2025",
    "clinicalAvailabilityCitations": "https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test",
    "complementaryTests": "Can add xR RNA sequencing, xF/xF+ liquid biopsy, HER2 IHC, PD-L1 IHC, HRD, Immune Profile Score",
    "complementaryTestsCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "numPublications": 50,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Validation study Oncotarget 2019 (Beaubier et al.); FDA CDx designation; widely used in clinical trials",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/31040929/"
  },
  {
    "id": "tds-6",
    "name": "Tempus xF",
    "vendor": "Tempus AI",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "approach": "Liquid CGP",
    "method": "ctDNA NGS panel targeting 105 genes; detects SNVs, indels, CNGs (6 genes), CNLs (BRCA1/2), and rearrangements (6 genes) plus MSI-H.",
    "methodCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/ | https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "analyticalValidation": "Validated performance metrics from Finkle et al. 2021 analytical validation study.",
    "analyticalValidationCitations": "https://www.tempus.com/wp-content/uploads/2021/09/xF-Validation-Summary.pdf",
    "genesAnalyzed": 105,
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "geneListUrl": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "biomarkersReported": ["SNVs", "Indels", "Select CNAs", "Select Rearrangements", "MSI"],
    "biomarkersReportedCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "targetPopulation": "Patients with advanced solid tumors; not intended for hematologic malignancies, early-stage cancers, or primary CNS malignancies",
    "targetPopulationCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer"],
    "vendorNCCNAlignmentNotes": "Covers key biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "5-7 days",
    "tatCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "sampleRequirements": "Blood in Streck cfDNA BCT tubes",
    "sampleRequirementsCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Commercial and Medicare coverage varies by indication.",
    "reimbursementCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "sensitivity": ">99% for SNVs/CNGs at ≥0.5% VAF; >98% for indels; >97% for rearrangements",
    "sensitivityCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "specificity": ">99.9% for SNVs, indels, rearrangements; >96% for CNGs",
    "specificityCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "numPublications": 20,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Validation study NPJ Precision Oncology 2021 (Finkle et al.); liquid biopsy clinical applications",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/34215841/"
  },
  {
    "id": "tds-7",
    "name": "Tempus xF+",
    "slug": "tempus-xf-plus",
    "vendor": "Tempus AI",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "approach": "Liquid CGP",
    "method": "Expanded ctDNA NGS panel targeting 523 genes; detects SNVs, indels, CNGs, and rearrangements; includes clonal hematopoiesis (CH) variant identification.",
    "methodCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "analyticalValidation": "Validated per Boulos et al. 2025 analytical validation study.",
    "analyticalValidationCitations": "https://pubmed.ncbi.nlm.nih.gov/39820598/",
    "genesAnalyzed": 523,
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "geneListUrl": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Rearrangements", "CH variants"],
    "biomarkersReportedCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "targetPopulation": "Patients requiring expanded liquid biopsy coverage",
    "targetPopulationCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.tempus.com/oncology/genomic-profiling/xf-plus/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Expanded 523-gene panel covers all biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "7-10 days",
    "tatCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "sampleRequirements": "Blood in Streck cfDNA BCT tubes",
    "sampleRequirementsCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "reimbursement": "Coverage Varies",
    "reimbursementCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Expanded panel; analytical validation J Mol Diagn 2025 (Boulos et al.)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/40287222/"
  },
  {
    "id": "tds-8",
    "name": "MSK-IMPACT",
    "slug": "msk-impact",
    "vendor": "Memorial Sloan Kettering",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS of matched tumor/normal FFPE tissue; targets 468 cancer-associated genes covering ~1.5Mb of the genome; detects SNVs, indels, CNAs, select rearrangements, and MSI.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf | https://www.mskcc.org/msk-impact",
    "genesAnalyzed": 468,
    "genesAnalyzedNotes": "468 genes in original FDA-authorized configuration (2017); panel has since expanded to ~505 genes per current MSK documentation.",
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf | https://ascopost.com/News/58263 | https://www.mskcc.org/msk-impact",
    "geneListUrl": "https://www.mskcc.org/msk-impact",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Select Rearrangements", "MSI"],
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.mskcc.org/msk-impact",
    "targetPopulation": "Patients with advanced cancer treated at Memorial Sloan Kettering Cancer Center",
    "targetPopulationCitations": "https://www.mskcc.org/msk-impact",
    "fdaStatus": "FDA authorized (de novo, DEN170058) November 2017 - First tumor-profiling LDT to receive FDA authorization",
    "fdaStatusCitations": "https://ascopost.com/News/58263 | https://www.mskcc.org/news/fda-authorizes-msk-impact-test-analyzing-patient-tumors",
    "fdaAuthorizationDate": "2017-11-15",
    "fdaAuthorizationDateCitations": "https://ascopost.com/News/58263",
    "fdaStatusNotes": "Not FDA-approved as CDx; authorized for tumor mutation profiling. Also approved by NYSDOH.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.mskcc.org/msk-impact",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Melanoma", "Ovarian Cancer", "Gastric Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "2-3 weeks",
    "tatCitations": "https://www.mskcc.org/msk-impact",
    "sampleRequirements": "FFPE tumor tissue plus matched normal sample",
    "sampleRequirementsNotes": "Tumor-normal matching allows accurate distinction of somatic vs germline variants.",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage depends on payer; available primarily to MSK patients.",
    "reimbursementCitations": "https://www.mskcc.org/msk-impact",
    "clinicalAvailability": "Available only at Memorial Sloan Kettering Cancer Center",
    "clinicalAvailabilityNotes": "Single-site assay; >20,000 patients sequenced since 2014. Results accessible via cBioPortal and annotated using OncoKB.",
    "clinicalAvailabilityCitations": "https://www.mskcc.org/msk-impact | https://www.mskcc.org/news-releases/msk-impact-first-tumor-profiling-multiplex-panel-authorized-fda-setting-new-pathway-market-future-oncopanels",
    "numPublications": 1000,
    "numPublicationsPlus": true,
    "numPublicationsSource": "vendor-estimate",
    "numPublicationsNotes": ">1,000 peer-reviewed publications featuring MSK-IMPACT data as of end of 2024 (vendor estimate).",
    "numPublicationsCitations": "https://www.mskcc.org/msk-impact",
    "publicationsExampleCitations": ["https://doi.org/10.1038/nm.4333", "https://doi.org/10.1056/NEJMoa1610624"],
    "keyFindings": "37% of profiled patients have at least one actionable mutation; 11% enrolled in matched clinical trials.",
    "keyFindingsCitations": "https://www.mskcc.org/news/fda-authorizes-msk-impact-test-analyzing-patient-tumors | https://www.cancer.gov/news-events/cancer-currents-blog/2017/genomic-profiling-tests-cancer"
  },
  {
    "id": "tds-9",
    "name": "MI Cancer Seek",
    "vendor": "Caris Life Sciences",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (WES + WTS)",
    "method": "Combined whole exome sequencing (WES) and whole transcriptome sequencing (WTS) from single FFPE tissue extraction; detects SNVs, indels in 228 genes, MSI, TMB, and ERBB2 amplification.",
    "methodCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC12581394/",
    "genesAnalyzed": 228,
    "genesAnalyzedNotes": "228 genes with reportable SNVs/indels in CDx subset; WES/WTS technically interrogates ~20,000 genes for research findings and signatures. This prevents confusion between '228 genes' and 'whole-exome' claims.",
    "genesAnalyzedCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",
    "geneListUrl": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",
    "biomarkersReported": ["SNVs", "Indels", "MSI", "TMB", "ERBB2 CNA"],
    "biomarkersReportedCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",
    "targetPopulation": "Adults and pediatric patients (ages 1-22) with previously diagnosed solid malignant neoplasms",
    "targetPopulationNotes": "First and only FDA-approved CGP with CDx indications for both adult and pediatric patients.",
    "targetPopulationCitations": "https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "fdaStatus": "FDA-approved IVD (P240010) November 2024 - First WES+WTS combined assay with CDx indications",
    "fdaStatusCitations": "https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/ | https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "fdaApprovalDate": "2024-11-06",
    "fdaApprovalDateCitations": "https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "fdaCompanionDxCount": 8,
    "fdaCompanionDxCountNotes": "8 CDx claims: 1 pan-cancer indication plus 5 tumor-specific indications (breast, colorectal, melanoma, NSCLC, endometrial). Includes PIK3CA, KRAS, NRAS, BRAF, MSI-H/TMB-H.",
    "fdaCompanionDxCountCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html | https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.molecularmd.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Endometrial Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines including PIK3CA, KRAS, NRAS, BRAF, MSI-H/TMB-H. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "14 days",
    "tatNotes": "Results within 14 days.",
    "tatCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",
    "sampleRequirements": "FFPE tissue; minimum 20% tumor content",
    "sampleRequirementsNotes": "Simultaneous DNA and RNA extraction from single sample minimizes tissue requirements compared to separate assays.",
    "sampleRequirementsCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/ | https://www.mlo-online.com/diagnostics/assays/news/55241478/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage expanding; contact Caris for current payer coverage.",
    "reimbursementCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",
    "clinicalAvailability": "Commercially available in US since November 2024",
    "clinicalAvailabilityCitations": "https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "analyticalValidation": "97-100% positive and negative percent agreement compared to other FDA-approved assays",
    "analyticalValidationCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",
    "numPublications": 30,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Part of Caris Molecular Intelligence platform (165+ total publications across platform)",
    "numPublicationsCitations": "https://www.carislifesciences.com/publications/"
  },
  {
    "id": "tds-11",
    "name": "OncoExTra",
    "vendor": "Exact Sciences",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (WES + WTS)",
    "method": "Whole exome sequencing (WES) of ~20,000 genes combined with whole transcriptome sequencing (WTS) from FFPE tissue; reports SNVs, indels, CNAs, fusions, MSI, TMB, and HRD status.",
    "methodCitations": "https://www.exactsciences.com/test/oncoextra | https://www.oncotarget.com/article/28285/text/",
    "genesAnalyzed": 20000,
    "genesAnalyzedNotes": "WES/WTS comprehensively interrogates ~20,000 genes; reportable subset varies by biomarker type.",
    "genesAnalyzedCitations": "https://www.exactsciences.com/test/oncoextra",
    "geneListUrl": "https://www.exactsciences.com/test/oncoextra",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "HRD"],
    "biomarkersReportedCitations": "https://www.exactsciences.com/test/oncoextra",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.exactsciences.com/test/oncoextra",
    "targetPopulation": "Patients with advanced solid tumors requiring comprehensive genomic and transcriptomic profiling",
    "targetPopulationCitations": "https://www.exactsciences.com/test/oncoextra",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.exactsciences.com/test/oncoextra",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.oncoextra.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer", "Melanoma"],
    "vendorNCCNAlignmentNotes": "WES/WTS approach covers all biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "10-14 days",
    "tatCitations": "https://www.exactsciences.com/test/oncoextra",
    "sampleRequirements": "FFPE tissue; 10 unstained slides or tissue block",
    "sampleRequirementsCitations": "https://www.exactsciences.com/test/oncoextra",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage; commercial coverage varies by payer.",
    "reimbursementCitations": "https://www.exactsciences.com/test/oncoextra",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.exactsciences.com/test/oncoextra",
    "clinicalUtility": "Studies demonstrate increased matched therapy rates compared to single-gene testing.",
    "clinicalUtilityCitations": "https://www.oncotarget.com/article/28285/text/ | https://pubmed.ncbi.nlm.nih.gov/37256839/",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Exact Sciences comprehensive profiling; emerging publication portfolio",
    "numPublicationsCitations": "https://www.exactsciences.com/test/oncoextra"
  },
  {
    "id": "tds-12",
    "name": "OmniSeq INSIGHT",
    "vendor": "Labcorp Oncology (OmniSeq)",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP + Immune Profiling",
    "method": "NGS panel covering full coding regions of 523 genes plus immune profiling including PD-L1 expression and immune signatures; detects SNVs, indels, CNAs, fusions, TMB, and MSI.",
    "methodCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight | https://pmc.ncbi.nlm.nih.gov/articles/PMC8796288/",
    "genesAnalyzed": 523,
    "genesAnalyzedCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "geneListUrl": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "PD-L1", "Immune Signatures"],
    "biomarkersReportedNotes": "Combined genomic and immune profiling in single test.",
    "biomarkersReportedCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "targetPopulation": "Patients with solid tumors requiring comprehensive genomic and immune profiling",
    "targetPopulationCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.omniseq.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Prostate Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines plus immune profiling. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "10-14 days",
    "tatCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "sampleRequirements": "FFPE tissue",
    "sampleRequirementsCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare and commercial coverage; widely available via Labcorp network.",
    "reimbursementCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "clinicalAvailability": "Commercially available in US via Labcorp network",
    "clinicalAvailabilityCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Labcorp Oncology (OmniSeq) platform publications",
    "numPublicationsCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8796288/"
  },
  {
    "id": "tds-13",
    "name": "StrataNGS",
    "vendor": "Strata Oncology",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Multiplex PCR/semiconductor sequencing panel targeting 429 genes; detects SNVs, indels, CNAs, select fusions, TMB, and MSI.",
    "methodCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088 | https://pubmed.ncbi.nlm.nih.gov/34723565/",
    "genesAnalyzed": 429,
    "genesAnalyzedCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088",
    "geneListUrl": "https://www.strataoncology.com/stratangs",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Select Fusions", "TMB", "MSI"],
    "biomarkersReportedCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.strataoncology.com/stratangs",
    "targetPopulation": "Patients with advanced solid tumors requiring genomic profiling",
    "targetPopulationCitations": "https://www.strataoncology.com/stratangs",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.strataoncology.com/stratangs",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.stratangs.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "7-10 days",
    "tatCitations": "https://www.strataoncology.com/stratangs",
    "sampleRequirements": "FFPE tissue",
    "sampleRequirementsCitations": "https://www.strataoncology.com/stratangs",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare-covered CGP; specific footprint in health-system networks.",
    "reimbursementCitations": "https://www.strataoncology.com/stratangs",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.strataoncology.com/stratangs",
    "clinicalUtility": "Published data on access and outcomes in real-world settings.",
    "clinicalUtilityCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088 | https://pubmed.ncbi.nlm.nih.gov/34723565/",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Strata Oncology clinical validation and utility studies",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/34723565/"
  },
  {
    "id": "tds-14",
    "name": "MI Profile",
    "vendor": "Caris Life Sciences",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue Multi-omic Profiling",
    "method": "Comprehensive multi-omic profiling combining WES, WTS, and protein analysis (IHC/FISH) from FFPE tissue; reports DNA variants, RNA fusions, and protein expression.",
    "methodCitations": "https://www.carislifesciences.com/physicians/profiling/ | https://www.carislifesciences.com/molecular-intelligence-platform/",
    "genesAnalyzed": 22000,
    "genesAnalyzedNotes": "WES/WTS interrogates ~22,000 genes; protein analysis adds expression-level biomarkers.",
    "genesAnalyzedCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "geneListUrl": "https://www.carislifesciences.com/physicians/profiling/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "Protein Expression"],
    "biomarkersReportedNotes": "Multi-omic approach combines genomic, transcriptomic, and proteomic data.",
    "biomarkersReportedCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "targetPopulation": "Patients requiring comprehensive multi-omic tumor profiling",
    "targetPopulationCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "fdaStatus": "CLIA LDT - MI Cancer Seek component FDA approved; full MI Profile is LDT",
    "fdaStatusNotes": "MI Cancer Seek (WES+WTS component) received FDA approval Nov 2024; MI Profile as comprehensive service remains CLIA LDT.",
    "fdaStatusCitations": "https://www.carislifesciences.com/physicians/profiling/ | https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.molecularmd.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Prostate Cancer", "Ovarian Cancer", "Gastric Cancer"],
    "vendorNCCNAlignmentNotes": "Multi-omic approach covers biomarkers recommended by NCCN guidelines at DNA, RNA, and protein levels. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "10-14 days",
    "tatCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "sampleRequirements": "FFPE tissue",
    "sampleRequirementsCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage varies by payer and specific tests ordered.",
    "reimbursementCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "numPublications": 100,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Caris flagship test; 165+ publications across platform per vendor",
    "numPublicationsCitations": "https://www.carislifesciences.com/publications/"
  },
  {
    "id": "tds-15",
    "name": "NEO PanTracer Tissue",
    "previousName": "Neo Comprehensive",
    "vendor": "NeoGenomics",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Comprehensive genomic profiling using DNA and RNA NGS; detects SNVs, indels, CNVs, fusions, splice variants, MSI, and TMB across 517 genes from FFPE tissue samples.",
    "methodCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/235/neogenomics-expands-ngs-portfolio-with-launch-of-neo | https://www.neogenomics.com/test-menu",
    "genesAnalyzed": 517,
    "genesAnalyzedNotes": "517 genes analyzed via both DNA and RNA NGS methods.",
    "genesAnalyzedCitations": "NeoGenomics press release March 2023; NeoGenomics test menu.",
    "geneListUrl": "https://www.neogenomics.com/test-menu",
    "biomarkersReported": ["SNVs", "Indels", "CNVs", "Fusions", "Splice variants", "TMB", "MSI"],
    "biomarkersReportedNotes": "Comprehensive biomarker detection including both DNA alterations and RNA fusions/splice variants.",
    "biomarkersReportedCitations": "NeoGenomics press release March 2023.",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.neogenomics.com/test-menu",
    "targetPopulation": "Patients with solid tumors requiring comprehensive genomic profiling for diagnosis, therapy selection, prognosis, and clinical trial eligibility",
    "targetPopulationCitations": "NeoGenomics test menu; press releases.",
    "fdaStatus": "CLIA LDT - NOT FDA approved",
    "fdaStatusNotes": "CLIA-certified and CAP-accredited laboratory-developed test. New York State approved (Jan 2024).",
    "fdaStatusCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/276/neogenomics-receives-new-york-state-approval-for-neo",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://neotrex.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Pan-cancer CGP aligns with NCCN guidelines for solid tumor biomarker testing. NCCN recommends testing specific genes/biomarkers but does not endorse specific commercial assays by name.",
    "tat": "7-10 days",
    "tatNotes": "Improved turnaround time compared to previous NeoGenomics panels. Streamlined workflow.",
    "tatCitations": "NeoGenomics press release March 2023.",
    "sampleRequirements": "FFPE tissue (decreased specimen requirements vs previous panels)",
    "sampleRequirementsCitations": "NeoGenomics press release March 2023.",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage varies by payer. Medicare coverage for CGP in advanced solid tumors. Commercial coverage varies.",
    "reimbursementCitations": "NeoGenomics website.",
    "clinicalAvailability": "Commercially available in US (including NY State)",
    "clinicalAvailabilityCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/276/neogenomics-receives-new-york-state-approval-for-neo",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "NeoGenomics tissue profiling panel; newer product (launched March 2023)",
    "numPublicationsCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/235/neogenomics-expands-ngs-portfolio-with-launch-of-neo",
    "regulatoryStatusNotes": "CAP-accredited and CLIA-certified laboratories in Fort Myers and Tampa, FL; Aliso Viejo and San Diego, CA; Research Triangle Park, NC; and Houston, TX. New York State approved January 2024."
  },
  {
    "id": "tds-16",
    "name": "Northstar Select",
    "vendor": "BillionToOne",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "approach": "Liquid CGP",
    "method": "Single-molecule NGS (smNGS) with QCT™ (Quantitative Counting Templates) for cfDNA analysis. 84-gene panel optimized for sensitivity over breadth. Detects SNVs, indels, CNAs (amplifications and losses), fusions, and MSI-H. Unique ability to differentiate focal copy number changes from aneuploidies using insights from >1 million cfDNA tests for fetal aneuploidy.",
    "methodCitations": "https://www.northstaronc.com/insights/introducing-northstar-select-a-liquid-biopsy-built-for-clinical-action | Bower X et al. J Liq Biopsy 2025;9:1003222",
    "genesAnalyzed": 84,
    "genesAnalyzedNotes": "84-gene panel: 82 genes for SNV/indels, 19 genes for CNA amplification, 5 genes for CNA loss, 9 genes for fusions. Panel designed for actionability over breadth.",
    "genesAnalyzedCitations": "https://www.northstaronc.com/",
    "geneListUrl": "https://cdn.prod.website-files.com/676903c0e34284138d6e0066/68e3c65e20bf5b7173202a4f_NS-SEL-FL-001-2509%20-%20Spec%20Sheet%20-%20DIGITAL.pdf",
    "biomarkersReported": ["SNVs", "Indels", "CNAs (amplification)", "CNAs (loss)", "Fusions", "MSI-H"],
    "biomarkersReportedNotes": "Reports guideline-recommended alterations with focus on actionability. Unique capability to detect CNA losses and differentiate focal driver amplifications from broad chromosomal aneuploidies.",
    "biomarkersReportedCitations": "https://www.northstaronc.com/ | Bower X et al. J Liq Biopsy 2025",
    "cancerTypes": ["Advanced solid tumors (17+ types)", "CNS cancers", "Low-shedding tumors"],
    "cancerTypesCitations": "https://www.prnewswire.com/news-releases/billiontoones-northstar-select-demonstrates-superior-sensitivity-in-prospective-head-to-head-validation-study-publication-302539192.html",
    "targetPopulation": "Patients with stage III or IV solid tumors requiring comprehensive genomic profiling, particularly when tissue is not feasible or for low-shedding tumors",
    "targetPopulationCitations": "https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072",
    "sensitivity": null,
    "sensitivityNotes": "In prospective head-to-head validation (n=182), detected 51% more pathogenic SNV/Indels and 109% more CNVs than comparator assays. 87% detection rate in CNS cancers vs 27-55% reported for other liquid biopsies. 91% of additional clinically actionable variants found below 0.5% VAF.",
    "sensitivityCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222 | https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072",
    "specificity": 99.9,
    "specificityNotes": ">99.9% analytical specificity across all variant classes. 98% concordance with ddPCR orthogonal validation. CHIP rate equivalent to comparators (19.0% vs 17.2%), confirming additional detections are true positives.",
    "specificityCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222",
    "lod": "0.15% VAF",
    "lodNotes": "LOD95 of 0.15% VAF for SNVs - among the lowest in commercially available liquid biopsy CGP. 2-5x lower LOD than comparator assays.",
    "lodCitations": "https://www.northstaronc.com/ | Bower X et al. J Liq Biopsy 2025",
    "fdaStatus": "CLIA LDT - NOT FDA approved",
    "fdaStatusNotes": "CLIA-certified laboratory-developed test. CAP-accredited.",
    "fdaStatusCitations": "https://www.northstaronc.com/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.biodesix.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer"],
    "vendorNCCNAlignmentNotes": "84-gene panel covers guideline-recommended biomarkers. NCCN recommends testing specific genes/biomarkers but does not endorse specific commercial assays by name.",
    "tat": "5-8 days",
    "tatNotes": "Typical turnaround time 5-8 days from specimen receipt.",
    "tatCitations": "https://www.northstaronc.com/insights/introducing-northstar-select-a-liquid-biopsy-built-for-clinical-action",
    "sampleRequirements": "Blood draw (plasma cfDNA)",
    "sampleRequirementsCitations": "https://www.northstaronc.com/",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via MolDx (Palmetto GBA LCD L38043) effective February 14, 2025 for eligible beneficiaries with advanced solid tumors.",
    "reimbursementCitations": "https://www.billiontoone.com/news-media/billiontoone-announces-medicare-coverage-for-northstar-select",
    "clinicalAvailability": "Commercially available in US since January 2023",
    "clinicalAvailabilityCitations": "https://www.delveinsight.com/asco-conference/article/billiontoone-northstar-select",
    "numPublications": 2,
    "numPublicationsNotes": "Peer-reviewed validation study published September 2025 in Journal of Liquid Biopsy. ASCO 2024 abstract.",
    "numPublicationsCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222 | JCO 2024;42:16_suppl,3072",
    "publicationsExampleCitations": ["https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00038-4/fulltext", "https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072"],
    "technologyDifferentiator": "Only liquid biopsy with prospective head-to-head peer-reviewed publication showing superior sensitivity vs multiple commercially available comparators. smNGS with QCT technology enables single-molecule precision. Unique ability to detect CNA losses and differentiate focal amplifications from aneuploidies.",
    "independentValidation": "Prospective head-to-head validation against 6 commercially available assays from 4 CLIA/CAP labs (n=182 patients, 17+ tumor types, 6 community clinics + 1 hospital). Orthogonal ddPCR validation showed 98% concordance.",
    "independentValidationCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222",
    "vendorDataSource": "Rob Manor (BillionToOne) submission Dec 2025"
  },
  {
    "id": "tds-18",
    "name": "IsoPSA",
    "vendor": "Cleveland Diagnostics",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Serum",
    "approach": "Protein Structure Analysis",
    "method": "IsoClear platform analyzes structural differences in PSA protein isoforms to distinguish cancer-derived PSA from benign elevations. Measures prostate cancer-specific structural variants of the PSA protein rather than total PSA concentration. Runs on standard clinical analyzers (Roche COBAS, Siemens, Abbott) enabling broad deployment from large centers to community practices.",
    "methodCitations": "Klein EA et al. Eur Urol 2017 | Stovsky M et al. J Urol 2019",
    "genesAnalyzed": null,
    "genesAnalyzedNotes": "Not applicable - protein structure analysis test, not genomic",
    "cancerTypes": ["Prostate cancer (high-grade)"],
    "cancerTypesNotes": "Specifically designed to detect high-grade (clinically significant) prostate cancer, helping avoid unnecessary biopsies for low-grade or benign conditions.",
    "targetPopulation": "Men ≥50 years of age with elevated PSA levels who are candidates for prostate biopsy decision-making",
    "targetPopulationCitations": "FDA PMA approval December 2025",
    "indicationsNotes": "Aid in the decision for prostate biopsy. Can be used prior to initial biopsy or in patients with prior negative biopsy who remain at elevated risk. Helps clinicians and patients make more informed biopsy decisions.",
    "sensitivity": 90.2,
    "sensitivityNotes": "90.2% sensitivity (95% CI: 86.4%-93.0%) for high-grade prostate cancer in prospective multicenter validation study (n=888).",
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data; https://pubmed.ncbi.nlm.nih.gov/27477528/ | Klein EA et al. Eur Urol 2017",
    "specificity": 45.5,
    "specificityNotes": "45.5% specificity (95% CI: 41.4%-49.6%) for high-grade prostate cancer. Specificity is 2-3x higher than traditional PSA tests, potentially avoiding up to 46% of unnecessary biopsies.",
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data; https://pubmed.ncbi.nlm.nih.gov/27477528/ | Klein EA et al. Eur Urol 2017",
    "ppv": 47.7,
    "ppvNotes": "47.7% PPV (95% CI: 45.7%-49.8%) for high-grade prostate cancer.",
    "ppvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data",
    "npv": 89.3,
    "npvNotes": "89.3% NPV (95% CI: 85.6%-92.2%) for high-grade prostate cancer, providing high confidence in negative results.",
    "npvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data",
    "auc": 0.783,
    "aucNotes": "AUC of 0.783 (95% CI: 0.752-0.814) for high-grade prostate cancer, outperforming total PSA and % free PSA.",
    "aucCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data",
    "fdaStatus": "FDA PMA Approved (December 2025)",
    "fdaStatusNotes": "FDA Premarket Approval (PMA) granted December 1, 2025. Previously offered as CLIA LDT since 2020. Breakthrough Device Designation granted October 2019.",
    "fdaStatusCitations": "https://www.businesswire.com/news/home/20251201324198/en/FDA-Approves-IsoPSA----Cleveland-Diagnostics-Novel-Blood-Based-Prostate-Cancer-Test",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Prostate Cancer Early Detection Guidelines (added V.1.2022, current)",
    "nccnGuidelinesNotes": "Specifically named for use prior to biopsy and in patients with prior negative biopsy at higher risk for clinically significant prostate cancer.",
    "nccnGuidelinesCitations": "https://www.businesswire.com/news/home/20220511005019/en/Cleveland-Diagnostics-Announces-Inclusion-of-IsoPSA-in-National-Comprehensive-Cancer-Network-Guidelines-for-Prostate-Cancer-Early-Detection",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage established. Commercial payer coverage for 140 million covered lives. More IsoPSAs ordered in first full year as LDT than Guardant360 tests in first 3 years.",
    "reimbursementCitations": "Cleveland Diagnostics; Sameer Rohatgi communication Dec 2025",
    "commercialPayers": ["Multiple commercial payers (140M covered lives)"],
    "tat": "3-5 days",
    "tatNotes": "Results typically available in 3-5 days from sample receipt.",
    "tatCitations": "https://www.isopsa.com/for-patients/",
    "sampleRequirements": "Blood draw in Streck tube",
    "sampleRequirementsNotes": "Simple blood draw collected in Streck tube. No DRE required prior to collection.",
    "sampleRequirementsCitations": "https://www.clevelanddx.com/isopsa-testing",
    "clinicalAvailability": "Commercially available in US (LDT since 2020, FDA PMA December 2025)",
    "clinicalAvailabilityNotes": "Available through Cleveland Diagnostics CLIA lab and Quest Diagnostics. IVD kit format enables deployment on standard clinical analyzers (Roche COBAS, Siemens, Abbott) at any laboratory.",
    "clinicalAvailabilityCitations": "https://www.clevelanddx.com",
    "availableRegions": ["US"],
    "clinicalTrials": "Prospective multicenter validation study (n=888 patients scheduled for prostate biopsy)",
    "clinicalTrialsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data; https://pubmed.ncbi.nlm.nih.gov/27477528/ | Klein EA et al. Eur Urol 2017",
    "totalParticipants": 888,
    "totalParticipantsNotes": "888 patients in prospective multicenter validation study. Additional longitudinal outcome data published in Urology 2025.",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Extensive publication portfolio including Klein EA et al. Eur Urol 2017 (initial validation), Stovsky M et al. J Urol 2019, decision analysis in Urol Pract 2022, and longitudinal outcomes in Urology 2025.",
    "numPublicationsCitations": "https://www.clevelanddx.com/news-archive",
    "publicationsExampleCitations": ["Klein EA et al. Eur Urol 2017", "Stovsky M et al. J Urol 2019", "Abdallah et al. Urology 2025"],
    "technologyDifferentiator": "Only FDA-approved protein structure-based cancer diagnostic. IsoClear platform measures structural differences in proteins rather than concentration. Deployable on standard clinical analyzers (Roche COBAS, Siemens, Abbott) enabling broad access from academic centers to community urology practices - not limited to centralized specialty labs.",
    "regulatoryStatusNotes": "FDA PMA approved December 2025. Breakthrough Device Designation 2019. In NCCN and AUA/SUO guidelines. First protein structure-based cancer blood test to receive FDA approval.",
    "vendorDataSource": "Sameer Rohatgi (Cleveland Diagnostics) communication Dec 2025"
  },
  {
    "id": "tds-19",
    "name": "Oncotype DX Breast Recurrence Score",
    "vendor": "Exact Sciences",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Gene Expression Profiling",
    "method": "21-gene RT-PCR assay analyzing expression of 16 cancer-related genes and 5 reference genes in FFPE tumor tissue; generates Recurrence Score (0-100) that is both prognostic for 9-year distant recurrence risk and predictive of adjuvant chemotherapy benefit.",
    "methodCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-providers | https://pubmed.ncbi.nlm.nih.gov/15591335/",
    "genesAnalyzed": 21,
    "genesAnalyzedNotes": "16 cancer-related genes (proliferation: Ki67, STK15, BIRC5, CCNB1, MYBL2; HER2 group: GRB7, HER2; estrogen: ER, PGR, BCL2, SCUBE2; invasion: MMP11, CTSL2; other: GSTM1, BAG1, CD68) plus 5 reference/housekeeping genes (ACTB, GAPDH, GUS, RPLPO, TFRC).",
    "genesAnalyzedCitations": "https://www.oncotarget.com/article/28148/text/",
    "geneListUrl": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-providers",
    "biomarkersReported": ["Gene Expression Score", "Recurrence Score (0-100)", "ER", "PR", "HER2"],
    "biomarkersReportedNotes": "Provides continuous Recurrence Score (0-100) predicting 9-year distant recurrence risk and chemotherapy benefit. Also reports quantitative RNA expression of ER, PR, and HER2.",
    "biomarkersReportedCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-providers",
    "cancerTypes": ["Breast cancer (HR+, HER2-)"],
    "cancerTypesNotes": "Indicated for early-stage (Stage I, II, IIIA), hormone receptor-positive, HER2-negative invasive breast cancer. Applicable to node-negative or node-positive (1-3 nodes) disease.",
    "cancerTypesCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-patients",
    "targetPopulation": "Patients with early-stage (Stage I-IIIA), HR+, HER2-, node-negative or node-positive (1-3 nodes) invasive breast cancer who are candidates for adjuvant systemic therapy",
    "targetPopulationCitations": "https://www.nccn.org/guidelines/category_1",
    "fdaStatus": "CLIA LDT - CAP-accredited, CLIA-certified; not FDA approved",
    "fdaStatusNotes": "Performed at Genomic Health (Exact Sciences) centralized laboratory in Redwood City, CA. CAP-accredited and CLIA-certified for high-complexity clinical laboratory testing. In clinical use since 2004.",
    "fdaStatusCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-invasive-ductal",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Breast Cancer Guidelines",
    "nccnGuidelinesNotes": "NCCN-preferred multigene assay with Category 1 evidence. Only test with Level 1 evidence for both prognosis AND prediction of chemotherapy benefit for HR+, HER2- breast cancer.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1",
    "otherGuidelinesRecommended": ["ASCO", "ESMO", "St Gallen", "NICE"],
    "otherGuidelinesNotes": "Incorporated into all major international breast cancer treatment guidelines including ASCO, ESMO, St Gallen Consensus, and NICE (UK). Only genomic assay with highest recommendation in 5 major international guidelines.",
    "otherGuidelinesCitations": "https://www.oncotypedxtest.com/healthcare-professionals/oncotype-dx-recommended-by-international-guidelines",
    "tat": "7-14 days",
    "tatNotes": "Results typically available within 7-10 days from specimen receipt at lab; approximately 2 weeks from sample collection. Performed at centralized Genomic Health laboratory in Redwood City, CA.",
    "tatCitations": "https://www.oncotypeiq.com/en-GB/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/how-to-order-a-test",
    "sampleRequirements": "FFPE tumor tissue from core biopsy, lumpectomy, or mastectomy; formalin-fixed; 5 μm unstained slides or tissue block",
    "sampleRequirementsNotes": "No additional procedure required - uses tissue already collected during biopsy or surgery. Specimen transported in specially prepared container to centralized laboratory.",
    "sampleRequirementsCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-patients",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare and majority of private insurers cover for eligible patients. Medicare FFS coverage for patients meeting clinical criteria. 80+ commercial health plans provide coverage. Exact Sciences Genomic Access Program (GAP) available for financial assistance.",
    "reimbursementCitations": "https://precisiononcology.exactsciences.com/billing-financial-coverage",
    "listPrice": 4000,
    "listPriceNotes": "Approximately $4,000-$4,500.",
    "listPriceCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5310948/",
    "cptCodes": "81519",
    "cptCodesNotes": "CPT 81519 for Oncotype DX Breast Recurrence Score; CPT 0045U for DCIS Score.",
    "cptCodesCitations": "https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=55230",
    "codeType": "PLA",
    "medicareRate": 3416,
    "medicareRateNotes": "Medicare reimbursement rate approximately $3,416.",
    "medicareRateCitations": "https://www.genomeweb.com/molecular-diagnostics/cms-restores-reimbursement-rate-oncotype-dx-breast-cancer-test",
    "medicareStatus": "Priced",
    "adltStatus": true,
    "availableRegions": ["US", "UK", "EU", "Canada", "Israel", "Japan", "Australia", "International"],
    "availableRegionsNotes": "Available in 90+ countries. Publicly funded in UK, Ireland, Switzerland, Spain, Israel, Greece, and Canada. Samples shipped to centralized Genomic Health laboratory in Redwood City, CA (US) for testing.",
    "availableRegionsCitations": "https://www.prnewswire.com/news-releases/publication-in-the-new-england-journal-of-medicine-confirms-that-tens-of-thousands-of-women-with-node-positive-early-stage-breast-cancer-can-avoid-chemotherapy-with-the-oncotype-dx-test-301435658.html",
    "clinicalAvailability": "Commercially available since 2004; over 1 million patients tested worldwide",
    "clinicalAvailabilityCitations": "https://www.exactsciences.com/en-gb/cancer-testing/oncotype-dx-tests",
    "clinicalTrials": "TAILORx (NCT00310180; 10,273 patients); RxPONDER (NCT01272037; 5,083 patients); NSABP B-14; NSABP B-20; transATAC; SWOG-8814",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT00310180 | https://clinicaltrials.gov/study/NCT01272037",
    "clinicalTrialsNotes": "Only multigene assay with Level 1 evidence from prospective randomized trials (TAILORx, RxPONDER) demonstrating prediction of chemotherapy benefit. TAILORx showed majority of node-negative patients can safely forgo chemotherapy; RxPONDER extended findings to node-positive postmenopausal patients.",
    "totalParticipants": 15000,
    "totalParticipantsNotes": "Over 15,000 patients in pivotal prospective trials (TAILORx + RxPONDER). Over 1 million patients tested commercially worldwide.",
    "numPublications": 500,
    "numPublicationsPlus": true,
    "numPublicationsSource": "pubmed-estimate",
    "numPublicationsNotes": "Over 500 peer-reviewed publications. Bibliometric analysis identified 530+ publications as of 2016; publication count has increased substantially since TAILORx (2018) and RxPONDER (2021) results.",
    "numPublicationsCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5459968/",
    "publicationsExampleCitations": ["Paik S et al. N Engl J Med 2004;351:2817-2826", "Sparano JA et al. N Engl J Med 2018;379:111-121", "Kalinsky K et al. N Engl J Med 2021;385:2336-2347"],
    "technologyDifferentiator": "First commercially available multigene assay for breast cancer (2004). Pioneered genomic-guided treatment decisions in oncology. Only test with Level 1 evidence from prospective randomized trials (TAILORx, RxPONDER) demonstrating prediction of chemotherapy benefit. Transformed standard of care by enabling personalized chemotherapy decisions, sparing hundreds of thousands of patients from unnecessary chemotherapy. Gene expression profiling approach (not mutation detection) - fundamentally different methodology from CGP tests.",
    "regulatoryStatusNotes": "CLIA-certified LDT in clinical use since 2004. Not FDA approved but considered standard of care with Category 1 NCCN recommendation. Incorporated into AJCC 8th edition pathological prognostic staging.",
    "historicalSignificance": "Pioneered the era of genomic-guided personalized cancer care for breast cancer. In clinical use for over 20 years with over 1 million patients tested globally.",
    "submissionInfo": {
      "submittedBy": "Dr. Don Johann",
      "submitterEmail": "djjohann@uams.edu",
      "submitterType": "Independent Expert",
      "submitterAffiliation": "University of Arkansas for Medical Sciences",
      "submissionDate": "2025-12-17",
      "submissionNotes": "Surprise you do not list this test, OncoType Dx, given the disruptive impact it has had since 2004. Please consider adding. This website is outstanding! Thank you."
    }
  },
  {
    "id": "tds-20",
    "name": "Liquid Trace Solid Tumor",
    "vendor": "Genomic Testing Cooperative (GTC)",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "EDTA",
    "approach": "Liquid CGP",
    "method": "Combined cfDNA and cfRNA NGS from peripheral blood or CSF. cfDNA analysis detects SNVs, indels, CNAs, and chromosomal structural abnormalities. cfRNA analysis (>1,600 genes) detects gene fusions, expression levels, and alternative splicing variants. Includes TMB evaluation, T/B-cell clonality, HLA Class I genotyping, and viral detection (EBV, HPV, TTV).",
    "methodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "methodNotes": "Unique cfDNA + cfRNA combination provides higher sensitivity than cfDNA-only liquid biopsies. cfRNA captures fusion genes from chromosomal translocations and expression-level changes that cfDNA misses. Studies show RNA sequencing is more sensitive for some mutations since cancer cells contain multiple RNA copies but only one mutated DNA copy.",
    "genesAnalyzed": 1600,
    "genesAnalyzedNotes": ">1,600 genes analyzed via cfRNA; cfDNA gene count not specified separately. Combined approach.",
    "genesAnalyzedCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "geneListUrl": "https://genomictestingcooperative.com/genomic-tests/cfdna-genes/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "Gene Expression", "TMB", "Chromosomal Abnormalities", "T/B-cell Clonality", "HLA Genotyping", "Viral (EBV, HPV, TTV)"],
    "biomarkersReportedNotes": "cfRNA enables fusion detection and expression profiling not available from cfDNA-only tests. Viral detection includes EBV (lymphoid neoplasms), HPV (anogenital/oropharyngeal cancers), and TTV (immune competence marker).",
    "biomarkersReportedCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "cancerTypes": ["Lung", "Brain/CNS", "Breast", "Thyroid", "Colorectal", "Oropharyngeal", "Pancreatic", "Ovarian", "Prostate", "Other solid tumors"],
    "cancerTypesCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "targetPopulation": "Patients with solid tumors requiring comprehensive genomic profiling for diagnosis, treatment selection, or monitoring. CSF samples accepted for CNS tumors (can add MGMT methylation analysis for brain tumors when tumor DNA detected).",
    "targetPopulationCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory developed test performed at GTC's CLIA/CAP-certified laboratory. NYSDOH approved. CE-marked for EU. UKCA certified for UK.",
    "fdaStatusCitations": "https://genomictestingcooperative.com/legal-licensing/licenses-cerifications/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://imagenedx.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Covers guideline-recommended biomarkers. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "5-7 days",
    "tatNotes": "RNA stability is 48-72 hours from blood draw; DNA stability is 7 days. Samples received beyond 72 hours may include only DNA results.",
    "tatCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "sampleRequirements": "Peripheral blood: 10mL in EDTA tube. CSF: 7-10mL optimal (5mL minimum). Ship blood with cold pack (not directly contacting tube) overnight.",
    "sampleRequirementsNotes": "For blood: RNA stability 48-72 hours, DNA stability 7 days. For CSF: Ship ASAP overnight, do not use anticoagulants, use clear tubes.",
    "sampleRequirementsCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "lod": "0.1-0.01% VAF (non-hotspot); 0.01-0.001% (hotspot); <0.001% (tumor-informed)",
    "lodNotes": "Detection sensitivity varies by variant type and prior history. Tumor-informed or prior history samples achieve highest sensitivity.",
    "lodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare covered. Contact GTC for current payer coverage information.",
    "availableRegions": ["US", "EU", "UK"],
    "availableRegionsNotes": "NYSDOH approved. CE-marked for EU. UKCA certified for UK. US-based laboratory with international representatives.",
    "availableRegionsCitations": "https://genomictestingcooperative.com/international-representatives/",
    "clinicalAvailability": "Commercially available",
    "clinicalAvailabilityCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "numPublications": 15,
    "numPublicationsNotes": "Publications from GTC team on cfDNA/cfRNA liquid biopsy methodology. References listed on product page.",
    "numPublicationsCitations": "https://genomictestingcooperative.com/category/publications/",
    "technologyDifferentiator": "Only commercially available liquid biopsy combining cfDNA and cfRNA analysis. cfRNA provides: (1) Higher sensitivity for some mutations due to multiple RNA copies per cell; (2) Fusion gene detection from chromosomal translocations; (3) Expression-level data including alternative splicing. Also includes T/B-cell clonality, HLA genotyping, and viral detection (EBV, HPV, TTV) not found in most liquid CGP tests. LEADING PROVIDER FOR CSF LIQUID BIOPSY - optimal sample input for CNS tumors (glioblastoma, CNS lymphomas/leukemias) and leptomeningeal disease (common in breast, lung, melanoma patients with prolonged survival). AI/machine learning integrated into analysis pipeline.",
    "monitoringCapabilities": true,
    "monitoringCapabilitiesNotes": "Reports include serial VAF tracking AND mutant molecules/mL for quantitative treatment response monitoring. Can be used for longitudinal disease monitoring in addition to initial genomic profiling.",
    "csfLeadership": true,
    "csfLeadershipNotes": "GTC is the leading provider of liquid biopsy on cerebrospinal fluid (CSF). CSF is the optimal sample for CNS tumors including glioblastoma, CNS lymphomas, CNS leukemias, and leptomeningeal disease which commonly occurs in breast, lung, and melanoma patients with prolonged survival.",
    "submissionInfo": {
      "submittedBy": "Jeffrey Owen",
      "submitterEmail": "jowen@genomictestingcooperative.com",
      "submitterType": "Vendor Representative",
      "submissionDate": "2025-12-17",
      "submissionNotes": "Submitted as TRM; also listed in TDS for CGP use case. Test is used for both initial profiling AND serial therapeutic monitoring via VAF/mutant molecules tracking.",
      "vendorUpdateDate": "2025-12-17",
      "vendorUpdateNotes": "Vendor clarified test is actively used for therapeutic monitoring with VAF and mutant molecules/mL tracking table in reports. Emphasized CSF leadership for CNS tumors and leptomeningeal disease."
    }
  },
  {
    "id": "tds-21",
    "name": "Liquid Trace Hematology",
    "vendor": "Genomic Testing Cooperative (GTC)",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "EDTA",
    "approach": "Liquid CGP",
    "method": "Combined cfDNA and cfRNA NGS from peripheral blood or CSF. Highly sensitive pan-cancer test for hematologic malignancies. cfRNA (>1,600 genes) enables detection of mutations and fusions often missed by cfDNA-only testing. Includes T/B-cell clonality detection, HLA Class I genotyping, and viral detection (TTV as immune competence marker).",
    "methodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "methodNotes": "Can significantly reduce need for bone marrow biopsies. Detects chromosomal abnormalities, translocations, and gene amplifications from liquid biopsy. CSF samples ideally suited for characterizing lymphoma and multiple myeloma with CNS involvement.",
    "genesAnalyzed": 1600,
    "genesAnalyzedNotes": ">1,600 genes analyzed via cfRNA; combined cfDNA + cfRNA approach.",
    "genesAnalyzedCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "geneListUrl": "https://genomictestingcooperative.com/genomic-tests/cfdna-genes/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "Gene Expression", "Chromosomal Abnormalities", "T/B-cell Clonality", "HLA Genotyping", "TTV Viral Load", "CAR-T Detection"],
    "biomarkersReportedNotes": "T/B-cell clonality detection important for diagnosis and monitoring of lymphoid and plasma cell malignancies. TTV (Torque Teno Virus) load serves as immune competence marker - high TTV associated with infection risk, low TTV with rejection risk in transplant patients. Can detect and monitor CAR-T cells in CSF.",
    "biomarkersReportedCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "cancerTypes": ["Multiple Myeloma", "Lymphoma", "Acute Lymphoblastic Leukemia (ALL)", "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasms (MPN)", "VEXAS Syndrome", "EBV-related Neoplasms", "Hypereosinophilia"],
    "cancerTypesCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "targetPopulation": "Patients with hematologic malignancies requiring comprehensive genomic profiling for diagnosis, classification, treatment selection, or monitoring. Alternative to bone marrow biopsy in many cases. CSF samples for CNS involvement characterization and CAR-T monitoring.",
    "targetPopulationCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory developed test performed at GTC's CLIA/CAP-certified laboratory. NYSDOH approved. CE-marked for EU. UKCA certified for UK.",
    "fdaStatusCitations": "https://genomictestingcooperative.com/legal-licensing/licenses-cerifications/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://imagenedx.com/",
    "vendorNCCNAlignmentIndications": ["Acute Myeloid Leukemia", "Multiple Myeloma", "B-Cell Lymphomas"],
    "vendorNCCNAlignmentNotes": "Covers guideline-recommended biomarkers for hematologic malignancies. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "5-7 days",
    "tatNotes": "RNA stability is 48-72 hours from blood draw; DNA stability is 7 days. Samples received beyond 72 hours may include only DNA results.",
    "tatCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "sampleRequirements": "Peripheral blood: 10mL in EDTA tube. CSF: 7-10mL optimal (5mL minimum). Ship blood with cold pack (not directly contacting tube) overnight.",
    "sampleRequirementsNotes": "For blood: RNA stability 48-72 hours, DNA stability 7 days. For CSF: Ship ASAP overnight, do not use anticoagulants, use clear tubes.",
    "sampleRequirementsCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "lod": "0.1-0.01% VAF (non-hotspot); 0.01-0.001% (hotspot); <0.001% (tumor-informed)",
    "lodNotes": "Detection sensitivity varies by variant type and prior history. VAF used to monitor disease - higher VAF indicates higher tumor load; reduction in VAF after treatment indicates response.",
    "lodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare covered. Contact GTC for current payer coverage information.",
    "availableRegions": ["US", "EU", "UK"],
    "availableRegionsNotes": "NYSDOH approved. CE-marked for EU. UKCA certified for UK. US-based laboratory with international representatives.",
    "availableRegionsCitations": "https://genomictestingcooperative.com/international-representatives/",
    "clinicalAvailability": "Commercially available",
    "clinicalAvailabilityCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "numPublications": 15,
    "numPublicationsNotes": "Publications from GTC team on cfDNA/cfRNA liquid biopsy methodology. References listed on product page.",
    "numPublicationsCitations": "https://genomictestingcooperative.com/category/publications/",
    "technologyDifferentiator": "Only commercially available hematology liquid biopsy combining cfDNA and cfRNA analysis. Can reduce need for bone marrow biopsies. Key differentiators: (1) cfRNA enables higher sensitivity and fusion detection; (2) T/B-cell clonality for lymphoid/plasma cell malignancy diagnosis; (3) TTV viral load as immune competence marker for transplant patients; (4) CAR-T cell detection and monitoring in CSF; (5) CSF samples for CNS involvement characterization; (6) cfDNA chimerism analysis for post-transplant relapse prediction; (7) Chromosomal abnormalities detection beyond mutations (going beyond Signatera-style mutation-only MRD). LEADING PROVIDER FOR CSF LIQUID BIOPSY in hematologic malignancies. AI/machine learning integrated into analysis pipeline.",
    "monitoringCapabilities": true,
    "monitoringCapabilitiesNotes": "Reports include serial VAF tracking AND mutant molecules/mL for treatment response monitoring. Published validation shows cfDNA detects MORE mutations than bone marrow (92 vs 61 mutations in same patients). Higher VAF = higher tumor load; VAF reduction = response to treatment.",
    "chimerismCapabilities": true,
    "chimerismCapabilitiesNotes": "cfDNA chimerism analysis for post-transplant monitoring. Published 2025 data (Rowley et al., Cancers) shows cfDNA chimerism predicts relapse more accurately than standard CD3+ cell chimerism. All relapsed patients showed downward trend in cfDNA chimerism detectable by day 56 post-transplant.",
    "mrdCapabilities": true,
    "mrdCapabilitiesNotes": "MRD detection via persistent adverse-risk driver mutations AND chromosomal abnormalities - going beyond mutation-only approaches like Signatera. Published data: patients who cleared adverse-risk mutations did not relapse; 6/7 patients with persistent adverse-risk mutations relapsed within 12 months post-transplant.",
    "csfLeadership": true,
    "csfLeadershipNotes": "Ideally suited for characterizing lymphoma and multiple myeloma with CNS involvement. Can detect and monitor CAR-T cells in CSF samples.",
    "submissionInfo": {
      "submittedBy": "Jeffrey Owen",
      "submitterEmail": "jowen@genomictestingcooperative.com",
      "submitterType": "Vendor Representative",
      "submissionDate": "2025-12-17",
      "submissionNotes": "Submitted alongside Liquid Trace Solid Tumor. Entered as separate test due to distinct cancer type focus and additional hematology-specific biomarkers (T/B clonality, TTV, CAR-T detection, chimerism).",
      "vendorUpdateDate": "2025-12-17",
      "vendorUpdateNotes": "Vendor clarified MRD approach includes chimerism analysis and chromosomal abnormalities beyond just mutations - differentiated from Signatera. Published 2025 papers on cfDNA chimerism predicting relapse post-transplant."
    },
    "publicationsKey": [
      {
        "citation": "Rowley SD, Albitar M, et al. cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Cancers 2025;17:625.",
        "url": "https://doi.org/10.3390/cancers17040625",
        "keyFinding": "cfDNA testing detected more mutations than bone marrow (92 vs 61); cfDNA chimerism predicted relapse better than CD3+ chimerism; adverse-risk mutation clearance = no relapse"
      },
      {
        "citation": "Aljurf M, et al. Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse.",
        "url": "https://genomictestingcooperative.com/chimerism-analysis-of-cell-free-dna/",
        "keyFinding": "cfDNA chimerism more reliable than cellular DNA chimerism for predicting early relapse post-HSCT"
      }
    ]
  },
  {
    "id": "tds-22",
    "name": "LiquidHALLMARK",
    "vendor": "Lucence",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "approach": "Liquid CGP (ctDNA + ctRNA)",
    "method": "Amplicon-based NGS (AmpliMark platform) of ctDNA (80 genes) and ctRNA (10 fusion targets); detects SNVs, indels, CNAs, MSI, and fusions with molecular barcode error correction. Combined ctDNA + ctRNA analysis increases actionable fusion detection by 36.7% vs ctDNA alone.",
    "methodCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811 | https://pubmed.ncbi.nlm.nih.gov/35482824/",
    "methodNotes": "AmpliMark proprietary technology uses unique molecular barcodes and error correction to maximize sensitivity. ctRNA addresses DNA-based fusion detection limitations from large introns. Available via Mayo Clinic Labs since March 2025.",
    "genesAnalyzed": 80,
    "genesAnalyzedNotes": "80 genes analyzed via ctDNA for SNVs, indels, CNAs, MSI. 10 genes analyzed via ctRNA for fusions.",
    "genesAnalyzedCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "rnaGenesAnalyzed": 10,
    "rnaGenesAnalyzedNotes": "10 ctRNA targets for actionable and emerging fusions: ALK, FGFR2, FGFR3, MET, NTRK1, NTRK2, RET, ROS1, TMPRSS2.",
    "rnaGenesAnalyzedCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "geneListUrl": "https://www.mayocliniclabs.com/it-mmfiles/LiquidHALLMARK-Targets-by-Cancer-Type.pdf",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "MSI"],
    "biomarkersReportedNotes": "MSI determined from 6 microsatellite loci (BAT25, BAT26, NR21, NR24, NR27, MONO27). MSI-H = 2+ sites, MSI-L = 1 site.",
    "biomarkersReportedCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "cancerTypes": ["Solid tumors (lung, breast, colon, prostate, ovarian, gastric, liver, pancreatic, bladder, kidney, thyroid, melanoma, endometrial, cervical, head & neck)"],
    "cancerTypesNotes": "Targets genes commonly associated with 15 cancer types.",
    "cancerTypesCitations": "https://www.lucence.com/solutions/liquid-hallmark | https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "targetPopulation": "Patients with solid tumors requiring genomic profiling when tissue biopsy is not feasible or as complement to tissue testing",
    "targetPopulationCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "lod": "0.1% VAF (SNVs/indels); 0.5% VAF (DNA fusions); 10 copies (RNA fusions)",
    "lodNotes": "At 0.1% VAF: >91% sensitivity for SNVs, >95% for indels. At 0.5% VAF: >91% sensitivity for DNA fusions. Copy number LoD: gain 0.6 copy (1.3-fold), loss 0.71 copy (1.4-fold). MSI LoD: 5% DNA with deletions-insertions in microsatellite loci.",
    "lodCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811 | https://pubmed.ncbi.nlm.nih.gov/35482824/",
    "sensitivity": 99.38,
    "sensitivityNotes": "99.38% sensitivity for SNVs at 0.1% VAF; 95.83% for indels at 0.1% VAF; >91% for fusions at 0.5% VAF. Performance validated using reference materials and 1,592 clinical samples.",
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/35482824/ | https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "specificity": 99,
    "specificityNotes": ">99% specificity across mutation classes at 0.1-5% VAF. 93.8% concordance with EGFR allele-specific PCR (n=355); 84% concordance with cobas EGFR v2 (n=50), 100% for VAF >0.4%.",
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/35482824/ | https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "fdaStatus": "CLIA LDT – NOT FDA approved",
    "fdaStatusNotes": "Laboratory developed test performed at Lucence Health Inc. CLIA-certified (05D2200843), CAP-accredited laboratory. Not cleared or approved by FDA.",
    "fdaStatusCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.luminexcorp.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer"],
    "vendorNCCNAlignmentNotes": "Covers 9 NCCN guideline-recommended biomarkers for NSCLC: EGFR, ALK, RET, ROS1, BRAF, KRAS, MET, ERBB2, NTRK1/2/3. LIQUIK study showed LiquidHALLMARK detected 15.6% more tissue-confirmed, NCCN guideline-recommended biomarkers than FDA-approved ctDNA-only test.",
    "tat": "8-12 days",
    "tatNotes": "Results typically available 8-12 days from receipt of specimen. Test performed Monday through Friday.",
    "tatCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "sampleRequirements": "20mL whole blood in 2x Streck cfDNA BCT tubes (10mL each); 4-day stability at ambient temperature",
    "sampleRequirementsNotes": "Do not centrifuge or aliquot. Invert tubes to mix blood. Ship at ambient temperature. Gross hemolysis, lipemia, or icterus will result in rejection.",
    "sampleRequirementsCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via MolDX (Palmetto GBA), effective October 2, 2024, for all stages of advanced solid tumors. First Asian company to secure Medicare coverage for liquid biopsy in US (Feb 2023 for NSCLC, expanded 2024). CPT code 0571U.",
    "reimbursementCitations": "https://www.lucence.com/lucencenews/lucence-secures-moldx-approval-for-liquidhallmark-ctdna-and-ctrna-liquid-biopsy-test-to-advance-non-invasive-cancer-diagnostics/ | https://www.lucence.com/lucencenews/lucence-confirms-comprehensive-medicare-coverage-for-liquidhallmark-and-demonstrates-sensitive-detection-of-lung-cancer-biomarkers-in-prospective-study/",
    "cptCodes": "0571U",
    "cptCodesCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "codeType": "PLA",
    "availableRegions": ["US", "Singapore", "International"],
    "availableRegionsNotes": "US: Available via Mayo Clinic Labs (since March 2025) and Lucence Palo Alto lab (CLIA 05D2200843). Singapore: Lucence headquarters with CLIA/CAP-certified lab. International: Turkey (via Omnigen), India (via Agilus Diagnostics). NOT available in NY State.",
    "availableRegionsCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811 | https://www.lucence.com/about",
    "clinicalAvailability": "Commercially available in US since 2021; available via Mayo Clinic Labs since March 2025",
    "clinicalAvailabilityCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811 | https://www.lucence.com/solutions/liquid-hallmark",
    "clinicalTrials": "LIQUIK (prospective multicenter NSCLC study, n=200, 7 US sites); VA Palo Alto Health Care System liquid biopsy screening study",
    "clinicalTrialsNotes": "LIQUIK primary endpoint: compare LiquidHALLMARK with tissue NGS for 9 guideline-recommended genes (EGFR, ALK, RET, ROS1, NTRK, MET, BRAF, ERBB2, KRAS) in treatment-naive metastatic NSCLC. Results published JCO Precision Oncology 2025.",
    "clinicalTrialsCitations": "https://ascopubs.org/doi/10.1200/PO-25-00181 | https://www.lucence.com/lucencenews/liquik-study-for-lung-cancer/",
    "totalParticipants": 1592,
    "totalParticipantsNotes": "Clinical validation cohort of 1,592 patients across 30+ cancer types (Poh et al. PLoS One 2022). LIQUIK prospective study enrolled 200 metastatic NSCLC patients across 7 US sites.",
    "totalParticipantsCitations": "https://pubmed.ncbi.nlm.nih.gov/35482824/ | https://ascopubs.org/doi/10.1200/PO-25-00181",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Key publications: Poh et al. PLoS One 2022 (analytical/clinical validation); Samol et al. JCO Precis Oncol 2025 (LIQUIK prospective study); Iams et al. JAMA Netw Open 2024 (multicancer cohort); Heeke et al. JTO Clin Res Rep 2025 (ALK ctRNA tracking); multiple ASCO/IASLC conference abstracts.",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/35482824/ | https://ascopubs.org/doi/10.1200/PO-25-00181 | https://pubmed.ncbi.nlm.nih.gov/38231028/",
    "technologyDifferentiator": "Combined ctDNA + ctRNA analysis increases actionable fusion detection by 36.7% vs ctDNA alone. AmpliMark proprietary amplicon-based sequencing with molecular barcode error correction enables ultrasensitive detection. ctRNA component addresses DNA-based fusion detection limitations from large introns. LIQUIK prospective study showed LiquidHALLMARK detected 15.6% more tissue-confirmed NCCN guideline-recommended biomarkers than FDA-approved ctDNA-only test with 93-100% agreement with tissue NGS. Available via Mayo Clinic Labs partnership since March 2025.",
    "publicationsKey": [
      {
        "citation": "Poh J, et al. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA. PLoS One. 2022;17(4):e0267389.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35482824/",
        "keyFinding": "99.38% sensitivity for SNVs, 95.83% for indels at 0.1% VAF. 74.8% of clinical samples harbored actionable biomarkers."
      },
      {
        "citation": "Samol J, et al. LiquidHallmark detects more tissue-confirmed guideline-recommended biomarkers in lung cancer: prospective multicenter study. JCO Precis Oncol. 2025;9:e2500181.",
        "url": "https://ascopubs.org/doi/10.1200/PO-25-00181",
        "keyFinding": "LiquidHALLMARK ctDNA+ctRNA detected 15.6% more tissue-confirmed NCCN biomarkers than FDA-approved ctDNA-only test. 93-100% agreement with tissue NGS."
      },
      {
        "citation": "Iams WT, et al. Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort. JAMA Netw Open. 2024;7(1):e2351700.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38231028/",
        "keyFinding": "Multicancer validation of liquid biopsy vs tissue profiling for guideline-recommended biomarkers."
      }
    ],
    "submissionInfo": {
      "submittedBy": "Jeremy Au",
      "submitterEmail": "jeremy.au@lucence.com",
      "submitterType": "Vendor Representative",
      "submissionDate": "2025-12-19",
      "submissionNotes": "New test submission via OpenOnco form. Performance data URLs provided: Mayo Clinic Labs catalog and Lucence website. Verified via Mayo Clinic Labs test catalog (LUCHM), Lucence press releases, PLoS One 2022 validation study, and JCO Precision Oncology 2025 LIQUIK study."
    }
  },
  {
    "id": "tds-23",
    "name": "Resolution ctDx FIRST",
    "vendor": "Agilent / Resolution Bioscience",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Cell-Free DNA BCT",
    "approach": "Liquid CGP (ctDNA)",
    "method": "Hybrid-capture NGS covering 109 genes for SNVs, indels, CNAs, and fusions. FDA-approved CDx for KRAS G12C (adagrasib) and EGFR tumor profiling in NSCLC. Professional services portion (CLIA, not FDA) includes comprehensive genomic profiling.",
    "methodCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/agilent-resolution-ctdx-first-p210040 | https://www.resolutionbio.com/assays/Resolution-ctDx-FIRST.html",
    "methodNotes": "First liquid biopsy NGS assay FDA-approved as CDx for adagrasib (KRAZATI). Single-site PMA performed at Resolution Bioscience CLIA lab in Kirkland, WA. Proprietary primer extension technology enables fusion detection without a priori knowledge of gene partner.",
    "genesAnalyzed": 109,
    "genesAnalyzedNotes": "109 genes: 103 with SNV/indel detection (64% with full CDS coverage), 54 with CNA detection, 13 with fusion detection.",
    "genesAnalyzedCitations": "https://www.resolutionbio.com/assays/Resolution-ctDx-FIRST.html",
    "geneListUrl": "https://www.resolutionbio.com/assays/Resolution-ctDx-FIRST.html",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions"],
    "biomarkersReportedNotes": "FDA-approved for KRAS G12C and EGFR SNVs/deletions. Professional services (CLIA) includes all 109 genes across 4 alteration types.",
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "cancerTypes": ["NSCLC"],
    "cancerTypesNotes": "FDA indication limited to NSCLC. Professional services portion applicable to other solid tumors per oncologist discretion.",
    "cancerTypesCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/agilent-resolution-ctdx-first-p210040",
    "targetPopulation": "Adults with locally advanced or metastatic NSCLC requiring KRAS G12C or EGFR mutation testing for targeted therapy selection",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040A.pdf",
    "sensitivity": 66.2,
    "sensitivityNotes": "66.2% PPA vs tissue for KRAS G12C (95% CI: 54.0-77.0%). EGFR variant PPA: 100% for L858R, 91.3% for exon 19 deletions, 88.9% for T790M vs ddPCR.",
    "sensitivityCitations": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057 | https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "specificity": 100,
    "specificityNotes": "100% NPA for KRAS G12C vs tissue (95% CI: 94.7-100%). Zero false positive rate demonstrated in FDA analytical validation.",
    "specificityCitations": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057 | https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "lod": "0.34-0.82% MAF",
    "lodNotes": "LOD95 for SNVs and indels in KRAS and EGFR at 15ng cfDNA input ranged from 0.34% to 0.82%. KRAS G12C detected at low MAF (0.11-0.40%) in validation samples.",
    "lodCitations": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057 | https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "fdaStatus": "FDA PMA approved (December 2022)",
    "fdaStatusNotes": "PMA P210040 approved December 12, 2022. CDx for KRAS G12C to identify NSCLC patients eligible for adagrasib (KRAZATI). Also FDA-approved for EGFR tumor profiling per professional guidelines.",
    "fdaStatusCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/agilent-resolution-ctdx-first-p210040",
    "fdaCompanionDxCount": 1,
    "fdaCompanionDxList": ["Adagrasib (KRAZATI) - KRAS G12C - NSCLC"],
    "fdaCompanionDxNotes": "First liquid biopsy NGS CDx approved for adagrasib. If plasma negative, FDA recommends reflex to tissue testing with FDA-approved test.",
    "fdaCompanionDxCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040A.pdf",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://resolutionbio.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC"],
    "vendorNCCNAlignmentNotes": "Covers NCCN-recommended biomarkers for NSCLC including KRAS G12C and EGFR. 109-gene panel includes ALK, ROS1, RET, BRAF, MET, ERBB2, NTRK1/2/3.",
    "tat": "~9 days",
    "tatNotes": "Based on ctDx platform performance; median TAT 9 days vs 20 days for tissue NGS in prospective NSCLC study.",
    "tatCitations": "https://doi.org/10.1093/jnci/djy156",
    "sampleRequirements": "Whole blood in Streck Cell-Free DNA BCT tubes; 7-day stability prior to plasma isolation",
    "sampleRequirementsNotes": "cfDNA stable at -20°C for 30 days. Nominal 50ng cfDNA input (allowable range 15-75ng). Agilent Resolution ctDx FIRST Blood Collection Kit also available.",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040A.pdf",
    "reimbursement": "Medicare + Commercial",
    "reimbursementNote": "Resolution ctDx platform covered by Medicare and private payors. FDA-approved CDx status supports coverage for NSCLC patients.",
    "reimbursementCitations": "https://www.resolutionbio.com/company/press/2021.01.11_resolution_mirati_cdx.html",
    "availableRegions": ["US"],
    "availableRegionsNotes": "Single-site PMA test performed at Resolution Bioscience CLIA lab, Kirkland, WA. Available via Quest Diagnostics network (Jan 2023). Specimens collected at 2,100+ Quest patient service centers nationwide.",
    "availableRegionsCitations": "https://clpmag.com/diagnostic-technologies/immunoassay/immunoassay-reagents-kits/quest-diagnostics-offers-agilents-resolution-ctdx-first-liquid-biopsy-test/",
    "clinicalAvailability": "Commercially available since December 2022 (FDA approval); Quest Diagnostics distribution since January 2023",
    "clinicalAvailabilityCitations": "https://www.investor.agilent.com/news-and-events/news/news-details/2022/Agilent-Resolution-ctDx-FIRST-Receives-FDA-Approval-as-a-Liquid-Biopsy-Companion-Diagnostic-Test-for-Advanced-Non-small-Cell-Lung-Cancer/default.aspx",
    "clinicalTrials": "KRYSTAL-1 (NCT03785249) - Phase 1/2 adagrasib trial used for CDx clinical validation",
    "clinicalTrialsNotes": "FDA approval based on analytical validation and bridging studies using KRYSTAL-1 patient samples. Demonstrated clinical benefit of adagrasib in KRAS G12C+ NSCLC patients identified by ctDx FIRST.",
    "clinicalTrialsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "totalParticipants": 1000,
    "totalParticipantsNotes": "Over 1,000 patients enrolled in ongoing prospective NSCLC study with Memorial Sloan Kettering Cancer Center demonstrating clinical response to plasma-directed therapy selection.",
    "totalParticipantsCitations": "https://www.resolutionbio.com/company/press/2021.01.11_resolution_mirati_cdx.html",
    "numPublications": 5,
    "numPublicationsNotes": "Key: ASCO 2022 abstract (JCO 40:16_suppl.3057), FDA SSED, Lung Cancer 2019 (fusion sensitivity comparison), Clin Cancer Res 2016 (bias-corrected sequencing), JNCI 2018 (prospective ctDNA therapy selection).",
    "numPublicationsCitations": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057 | https://doi.org/10.1016/j.lungcan.2019.06.004 | https://doi.org/10.1093/jnci/djy156",
    "publicationsKey": [
      {
        "citation": "Pekker I, et al. Resolution ctDx FIRST plasma assay as a companion diagnostic for adagrasib. J Clin Oncol. 2022;40(16_suppl):3057.",
        "url": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057",
        "keyFinding": "66.2% PPA and 100% NPA for KRAS G12C vs tissue. LOD95 0.34-0.82% MAF. High concordance with ddPCR for EGFR variants."
      },
      {
        "citation": "Supplee JG, et al. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. Lung Cancer. 2019;134:96-99.",
        "url": "https://doi.org/10.1016/j.lungcan.2019.06.004",
        "keyFinding": "ctDx platform detected fusions missed by other assays due to inverted/out-of-frame variants. Superior fusion detection vs Guardant360."
      },
      {
        "citation": "Leighl NB, et al. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic NSCLC. Clin Cancer Res. 2019;25(15):4691-4700.",
        "url": "https://doi.org/10.1158/1078-0432.CCR-19-0624",
        "keyFinding": "Prospective study demonstrating clinical utility of ctDNA-directed therapy selection in metastatic NSCLC."
      }
    ],
    "technologyDifferentiator": "First FDA-approved liquid biopsy NGS CDx for KRAS G12C inhibitor (adagrasib). Proprietary primer extension technology detects fusions without prior knowledge of gene partner. Quest Diagnostics distribution enables broad US access via 2,100+ patient service centers. Zero false positive rate for CDx biomarkers in FDA validation. Superior fusion detection vs competitors in head-to-head studies.",
    "vendorRequestedChanges": "Dec 24, 2025: Added via LLM review pipeline recommendation - test identified as missing from OpenOnco database despite FDA CDx approval in December 2022."
  },
  {
    "id": "tds-24",
    "name": "OncoCompass Target",
    "vendor": "Burning Rock Dx (brbiotech)",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "approach": "Tumor-agnostic",
    "method": "Capture-based NGS panel targeting 168 genes from cfDNA; detects SNVs, indels, CNAs, and fusions",
    "methodCitations": "https://doi.org/10.1016/S2213-2600(18)30264-9",
    "genesAnalyzed": 168,
    "genesAnalyzedNotes": "168-gene panel (LDT version); CE-marked version covers 101 genes",
    "genesAnalyzedCitations": "https://doi.org/10.1016/S2213-2600(18)30264-9",
    "cancerTypes": ["NSCLC", "Pan-solid tumor"],
    "cancerTypesNotes": "Primary validation in metastatic NSCLC (BENEFIT trial); applicable to pan-solid tumors for CGP",
    "cancerTypesCitations": "https://doi.org/10.1016/S2213-2600(18)30264-9",
    "sensitivity": 96,
    "sensitivityPlus": true,
    "sensitivityNotes": "Analytical sensitivity for variant detection. 101-gene validation: 97.5% by-variant sensitivity in 904-patient cohort (Fan et al. 2024)",
    "sensitivityCitations": "https://doi.org/10.1002/cam4.70078 | Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "specificity": 99.9,
    "specificityNotes": "From 101-gene panel validation (n=904). Vendor reports 100% for 168-gene panel.",
    "specificityCitations": "https://doi.org/10.1002/cam4.70078 | Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "lod": "0.3% VAF (SNV/Indel), 2.5 copies (CNV), 0.3% (fusions)",
    "lodNotes": "Vendor data. 101-gene validation: LOD 0.38% SNV, 0.33% InDel, 0.33% fusion",
    "lodCitations": "https://doi.org/10.1002/cam4.70078 | Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "fdaStatus": "CLIA LDT / CE-IVD (101-gene version)",
    "fdaStatusNotes": "168-gene panel offered as LDT from Burning Rock laboratory. CE-marked 101-gene version available internationally.",
    "tat": 9,
    "tatNotes": "9 calendar days",
    "tatCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "listPrice": "Varies by region",
    "listPriceNotes": "Regional pricing structure",
    "listPriceCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "clinicalAvailability": "Commercially available in China and international markets via Burning Rock Dx laboratory",
    "clinicalAvailabilityNotes": "Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR)",
    "clinicalTrials": "NCT02282267 (BENEFIT)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/ct2/show/NCT02282267",
    "totalParticipants": 426,
    "totalParticipantsNotes": "BENEFIT trial: 426 screened, 188 enrolled",
    "numPublications": 129,
    "numPublicationsNotes": "Used in 100+ clinical studies. Key journals: Nature Medicine, Nature Biotechnology, Lancet Respiratory Medicine, Annals of Oncology, JAMA Network Open",
    "numPublicationsCitations": "https://doi.org/10.1016/S2213-2600(18)30264-9 | Vendor-provided publication list (Dec 2025)",
    "isRUO": false,
    "isClinicalLDT": true,
    "vendorVerified": false,
    "vendorRequestedChanges": "2025-01-01: Initial submission from Liankai Chi, PhD, Senior Marketing Manager, Burning Rock Dx. Performance data and 129-paper publication list provided. Primary validation: BENEFIT trial (Lancet Respir Med 2018, PMID 30017884)."
  },
  {
    "id": "tds-25",
    "name": "OncoScreen Focus CDx",
    "vendor": "Burning Rock Dx (brbiotech)",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS panel targeting 13 genes from FFPE tissue; detects SNVs, indels, CNAs, and fusions",
    "methodCitations": "https://us.brbiotech.com/fixed-panels/",
    "genesAnalyzed": 13,
    "genesAnalyzedNotes": "13 genes: EGFR, ALK, ROS1, RET, MET, ERBB2, BRAF, PIK3CA, KRAS, NRAS, HRAS, KIT, PDGFRA",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions"],
    "cancerTypes": ["NSCLC", "CRC", "GIST"],
    "cancerTypesNotes": "Focused panel for lung cancer therapy selection; covers key actionable genes for NSCLC, colorectal cancer, and gastrointestinal stromal tumors",
    "cancerTypesCitations": "https://us.brbiotech.com/fixed-panels/",
    "fdaStatus": "CLIA LDT (US); CE-IVD kit version available",
    "fdaStatusNotes": "Central lab service offered from Burning Rock laboratory. CE-marked IVD kit version (OncoScreen Focus CDx Tissue Kit) available separately.",
    "clinicalAvailability": "Commercially available via Burning Rock Dx laboratory",
    "clinicalAvailabilityNotes": "Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR)",
    "isRUO": false,
    "isClinicalLDT": true,
    "tat": "7-10 business days",
    "tatNotes": "Estimated TAT based on central lab NGS workflow. Burning Rock's Magnis BR automation system enables 3-day TAT in hospital settings.",
    "tatCitations": "https://www.prnewswire.com/news-releases/burning-rock-dx-launches-magnis-br-to-innovate-total-process-automation-for-ngs-testing-300960507.html",
    "numPublications": 5,
    "numPublicationsNotes": "Burning Rock has 62+ publications in PubMed mentioning their NGS panels broadly. OncoScreen Focus-specific publications estimated at 5+.",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/?term=%22Burning+Rock%22+NGS",
    "vendorVerified": false,
    "vendorRequestedChanges": "2025-01-01: Initial submission from Liankai Chi, PhD, Senior Marketing Manager, Burning Rock Dx. Originally rejected as tissue-only; scope expanded to include tissue tests."
  },
  {
    "id": "tds-kit-1",
    "name": "TruSight Oncology Comprehensive (TSO Comp)",
    "vendor": "Illumina",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "NextSeq 550Dx",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS covering 517 genes; detects SNVs, indels, CNAs, fusions/rearrangements; reports TMB, MSI status",
    "genesAnalyzed": 517,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "First FDA-approved distributable CGP IVD kit. Enables hospitals to bring comprehensive genomic profiling in-house. CE-IVD since March 2022.",
    "fdaStatus": "FDA-approved (Aug 2024); CE-IVD",
    "fdaCompanionDxCount": 2,
    "fdaCompanionDxNotes": "FDA approval includes CDx claims for NTRK fusions (pan-tumor) and RET fusions (NSCLC). TMB and MSI reported as biomarkers but not CDx-labeled. Additional CDx claims may expand post-approval.",
    "tmb": "Yes",
    "tmbNotes": "TMB calculated and reported; supports pembrolizumab TMB-H indication",
    "msi": "Yes",
    "msiNotes": "MSI status determined from NGS data",
    "reimbursement": "Medicare LCD (MolDX)",
    "commercialPayers": ["UnitedHealthcare", "Aetna", "Cigna"],
    "clinicalAvailability": "FDA-approved IVD kit",
    "tat": "10-14 days",
    "totalParticipants": 10000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "First FDA-approved pan-cancer CGP IVD kit. Enables decentralized in-house CGP testing at hospitals with NextSeq 550Dx. Complete workflow solution with TruSight Oncology Analysis software."
  },
  {
    "id": "tds-kit-2",
    "name": "GeneseeqPrime",
    "vendor": "Geneseeq Technology",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq/NovaSeq",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS panel covering 425 cancer-related genes; detects SNVs, indels, CNAs, fusions; reports TMB and MSI",
    "genesAnalyzed": 425,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "FDA 510(k) cleared August 2025 (K-number pending publication). Also CE-IVDR and NMPA (China) approved. First Chinese CGP to receive FDA clearance.",
    "fdaStatus": "FDA 510(k) cleared (Aug 2025); CE-IVDR; NMPA",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Emerging - new FDA clearance",
    "clinicalAvailability": "FDA-cleared IVD kit",
    "tat": "7-10 days",
    "totalParticipants": 50000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Global regulatory approvals (FDA, CE-IVDR, NMPA). Fresh FDA clearance (Sep 2025). Established in Asia market with US expansion. Competitive pricing expected."
  },
  {
    "id": "tds-kit-3",
    "name": "PGDx elio tissue complete",
    "vendor": "Labcorp (Personal Genome Diagnostics)",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq 550Dx",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS covering ~500 genes; comprehensive solid tumor profiling including SNVs, indels, CNAs, MSI, TMB",
    "genesAnalyzed": 505,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "FDA-cleared and CE-IVDR (July 2025). First and only test CE-marked for comprehensive solid tumor profiling under new EU IVDR regulation.",
    "fdaStatus": "FDA-cleared; CE-IVDR (Jul 2025)",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Medicare LCD coverage",
    "commercialPayers": ["UnitedHealthcare", "Aetna"],
    "clinicalAvailability": "FDA-cleared IVD kit",
    "tat": "10-14 days",
    "totalParticipants": 5000,
    "numPublications": 30,
    "technologyDifferentiator": "First CE-IVDR comprehensive CGP kit. Part of elio platform family including plasma focus Dx for liquid biopsy. PGDx analytics platform included."
  },
  {
    "id": "tds-kit-4",
    "name": "Oncomine Comprehensive Assay Plus",
    "vendor": "Thermo Fisher Scientific",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Ion GeneStudio S5",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Amplicon-based NGS covering 500+ genes from DNA and RNA; detects SNVs, indels, CNAs, and fusions including novel fusions via RNA",
    "genesAnalyzed": 500,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "Primarily positioned for oncology research. DNA+RNA workflow captures both mutation and fusion biomarkers. Popular choice for labs with Ion Torrent infrastructure. CE-IVD/IVDR status requires verification.",
    "fdaStatus": "RUO in US; CE-IVD status pending verification",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Coverage varies",
    "clinicalAvailability": "CE-IVD kit",
    "tat": "5-7 days",
    "totalParticipants": 20000,
    "numPublications": 80,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Ion Torrent amplicon-based sequencing - lower DNA input requirements than hybrid-capture. DNA+RNA workflow in single assay. Strong in APAC market. Automated Genexus workflow option available."
  },
  {
    "id": "tds-kit-5",
    "name": "TSO 500",
    "vendor": "Illumina",
    "productType": "Research Use Kit",
    "platformRequired": "NextSeq 500/550/550Dx",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS covering 523 genes from DNA and RNA; comprehensive detection of SNVs, indels, CNAs, fusions, TMB, MSI",
    "genesAnalyzed": 523,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "RUO (Research Use Only) comprehensive genomic profiling panel for clinical research. Predecessor to TSO Comprehensive (FDA-approved IVD). For clinical diagnostic use, use TSO Comprehensive.",
    "fdaStatus": "RUO",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Coverage varies",
    "clinicalAvailability": "RUO kit for clinical research",
    "tat": "7-10 days",
    "totalParticipants": 50000,
    "numPublications": 200,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Widely deployed RUO CGP panel with extensive real-world use in clinical research. DNA+RNA enrichment in single workflow. Foundation for TSO Comprehensive (IVD version)."
  },
  {
    "id": "tds-kit-6",
    "sampleCategory": "Blood/Plasma",
    "name": "cobas EGFR Mutation Test v2",
    "vendor": "Roche",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "cobas 4800/6800/8800 System",
    "approach": "Tumor-agnostic",
    "method": "Real-time PCR detection of 42 EGFR mutations including exon 19 deletions, L858R, T790M resistance mutation, and exon 20 insertions",
    "genesAnalyzed": 1,
    "genesAnalyzedNotes": "Single-gene test targeting EGFR only (42 specific mutations)",
    "cancerTypes": ["NSCLC"],
    "targetPopulation": "NSCLC patients for EGFR TKI therapy selection",
    "indicationsNotes": "FDA-approved companion diagnostic for multiple EGFR TKIs. First liquid biopsy test FDA-approved (June 2016). Detects T790M resistance mutation for osimertinib eligibility.",
    "sensitivity": 85,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150047C.pdf",
    "sensitivityNotes": "~85% concordance with tissue for EGFR mutations in plasma. Per FDA approval studies.",
    "specificity": 98,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150047C.pdf",
    "lod": "0.1% MAF",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150047C.pdf",
    "lodNotes": "Limit of detection varies by mutation; generally 0.1-1% mutant allele frequency",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Liquid biopsy - plasma cfDNA; also validated for tissue",
    "requiresMatchedNormal": "No",
    "tat": "1-2 days",
    "leadTimeVsImaging": null,
    "fdaStatus": "FDA-approved CDx (tissue 2013, plasma 2016)",
    "reimbursement": "Medicare covered as CDx",
    "clinicalAvailability": "FDA-approved IVD kit",
    "totalParticipants": 50000,
    "numPublications": 200,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Gold standard EGFR liquid biopsy kit. First FDA-approved liquid biopsy CDx. Distributed IVD kit for labs with cobas system. Rapid TAT (1-2 days) vs. NGS-based tests."
  },
  {
    "id": "tds-kit-7",
    "sampleCategory": "Blood/Plasma",
    "name": "cobas KRAS Mutation Test",
    "vendor": "Roche",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "cobas 4800 System",
    "approach": "Tumor-agnostic",
    "method": "Real-time PCR detection of KRAS mutations in codons 12, 13, and 61",
    "genesAnalyzed": 1,
    "genesAnalyzedNotes": "Single-gene test targeting KRAS only (codons 12, 13, 61)",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "mCRC patients for anti-EGFR therapy selection",
    "indicationsNotes": "FDA-approved companion diagnostic for cetuximab and panitumumab. KRAS wild-type required for anti-EGFR therapy eligibility.",
    "sensitivity": 95,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110027C.pdf",
    "sensitivityNotes": "High concordance with tissue testing. Per FDA approval data.",
    "specificity": 99,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110027C.pdf",
    "lod": "1% MAF",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110027C.pdf",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "1-2 days",
    "fdaStatus": "FDA-approved CDx",
    "reimbursement": "Medicare covered as CDx",
    "clinicalAvailability": "FDA-approved IVD kit",
    "totalParticipants": 20000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Rapid PCR-based KRAS testing for CRC. Distributed IVD kit enables in-house testing. Essential for anti-EGFR therapy decisions."
  },
  {
    "id": "tds-kit-8",
    "sampleCategory": "Blood/Plasma",
    "name": "therascreen EGFR RGQ PCR Kit",
    "vendor": "QIAGEN",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Rotor-Gene Q MDx",
    "approach": "Tumor-agnostic",
    "method": "Scorpions ARMS real-time PCR for EGFR exon 19 deletions, L858R, T790M, and other sensitizing mutations",
    "genesAnalyzed": 1,
    "genesAnalyzedNotes": "Single-gene test targeting EGFR only",
    "cancerTypes": ["NSCLC"],
    "targetPopulation": "NSCLC patients for EGFR TKI therapy selection",
    "indicationsNotes": "CE-IVD marked. Widely used in EU and Asia. FDA-approved for tissue; CE-IVD for plasma.",
    "sensitivity": 80,
    "sensitivityCitations": "https://www.qiagen.com/us/products/diagnostics-and-clinical-research/oncology/therascreen-egfr",
    "sensitivityNotes": "~80% sensitivity for major EGFR mutations in plasma per validation studies",
    "specificity": 98,
    "specificityCitations": "https://www.qiagen.com/us/products/diagnostics-and-clinical-research/oncology/therascreen-egfr",
    "lod": "1% MAF",
    "lodCitations": "https://www.qiagen.com/us/products/diagnostics-and-clinical-research/oncology/therascreen-egfr",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "1 day",
    "fdaStatus": "FDA-approved (tissue); CE-IVD (plasma)",
    "reimbursement": "Coverage varies by region",
    "clinicalAvailability": "CE-IVD kit; FDA-approved for tissue",
    "totalParticipants": 30000,
    "numPublications": 150,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Rotor-Gene Q platform common in many molecular labs. Rapid same-day results. Lower capital equipment cost than cobas system."
  },
  {
    "id": "tds-kit-9",
    "sampleCategory": "Blood/Plasma",
    "name": "OncoBEAM RAS CRC Kit",
    "vendor": "Sysmex Inostics",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "OncoBEAM System",
    "approach": "Tumor-agnostic",
    "method": "BEAMing (Beads, Emulsion, Amplification, Magnetics) digital PCR for extended RAS panel including KRAS exons 2-4 and NRAS exons 2-4",
    "genesAnalyzed": 2,
    "genesAnalyzedNotes": "Two-gene panel: KRAS (exons 2-4) and NRAS (exons 2-4)",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "mCRC patients for anti-EGFR therapy selection",
    "indicationsNotes": "CE-IVD marked for RAS testing in mCRC. Extended RAS panel covers all clinically relevant mutations. Ultra-sensitive digital PCR platform.",
    "sensitivity": 95,
    "sensitivityCitations": "https://www.sysmex-inostics.com/oncobeam-ras-crc",
    "sensitivityNotes": "BEAMing digital PCR provides high sensitivity for low-frequency mutations",
    "specificity": 99,
    "specificityCitations": "https://www.sysmex-inostics.com/oncobeam-ras-crc",
    "lod": "0.02% MAF",
    "lodCitations": "https://www.sysmex-inostics.com/oncobeam-ras-crc",
    "lodNotes": "Digital PCR achieves 0.02% MAF sensitivity - among the most sensitive RAS tests",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "3-5 days",
    "fdaStatus": "CE-IVD",
    "reimbursement": "Coverage varies; reimbursed in EU",
    "clinicalAvailability": "CE-IVD kit",
    "totalParticipants": 10000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Ultra-sensitive digital PCR (BEAMing) achieves 0.02% MAF - one of the most sensitive RAS liquid biopsy tests. Extended RAS panel for comprehensive therapy selection."
  },
  {
    "id": "tds-kit-10",
    "sampleCategory": "Blood/Plasma",
    "name": "PGDx elio plasma focus Dx",
    "vendor": "Labcorp (Personal Genome Diagnostics)",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq 550Dx",
    "approach": "Tumor-agnostic",
    "method": "NGS-based ~70-gene ctDNA panel; detects SNVs, indels, CNAs, and select fusions across pan-solid tumor biomarkers",
    "genesAnalyzed": 70,
    "genesAnalyzedNotes": "Approximately 70 genes covering pan-solid tumor biomarkers",
    "cancerTypes": ["Pan-solid tumor"],
    "targetPopulation": "Advanced solid tumor patients for therapy selection",
    "indicationsNotes": "FDA De Novo authorized - first FDA-authorized pan-tumor liquid biopsy IVD kit. Enables decentralized NGS liquid biopsy testing.",
    "sensitivity": 90,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN200058.pdf",
    "sensitivityNotes": "≥90% analytical sensitivity across variant types at LoD; multi-gene panel sensitivity varies by biomarker and VAF",
    "specificity": 95,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN200058.pdf",
    "specificityNotes": "≥95% analytical specificity in validation studies; >99.9% NPV across variant types",
    "lod": "0.5% MAF",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN200058.pdf",
    "lodNotes": "Analytical sensitivity ~0.5% VAF for most variants",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "5-7 days",
    "fdaStatus": "FDA De Novo authorized",
    "reimbursement": "Medicare LCD coverage",
    "clinicalAvailability": "FDA-authorized IVD kit",
    "totalParticipants": 5000,
    "numPublications": 30,
    "technologyDifferentiator": "First FDA-authorized pan-tumor liquid biopsy IVD kit. Enables hospitals to bring NGS liquid biopsy in-house. Part of elio platform including tissue CGP (elio tissue complete)."
  },
  {
    "id": "tds-kit-11",
    "sampleCategory": "Bone Marrow/Blood",
    "name": "LeukoStrat CDx FLT3 Mutation Assay",
    "vendor": "Invivoscribe",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "ABI 3500 Genetic Analyzer",
    "approach": "Targeted CDx",
    "method": "PCR-based detection of FLT3-ITD and TKD mutations; FDA-approved companion diagnostic",
    "genesAnalyzed": 1,
    "genesAnalyzedNotes": "Single-gene test targeting FLT3 only (ITD and TKD mutations)",
    "cancerTypes": [
      "AML"
    ],
    "targetPopulation": "AML patients for FLT3-targeted therapy selection",
    "indicationsNotes": "FDA-approved companion diagnostic for VANFLYTA (quizartinib), RYDAPT (midostaurin), and XOSPATA (gilteritinib). Primary use is therapy selection at diagnosis.",
    "sensitivity": null,
    "sensitivityNotes": "Designed for mutation detection at diagnosis; sensitivity depends on allelic ratio",
    "lod": "5% ITD ratio",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160040C.pdf | https://www.invivoscribe.com/products/leukostrat-cdx-flt3-mutation-assay",
    "lodNotes": "Clinical cutoff for FLT3-ITD positivity",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Uses bone marrow or peripheral blood directly",
    "requiresMatchedNormal": "No",
    "tat": "3 days",
    "fdaStatus": "FDA-approved CDx; CE-IVDR",
    "reimbursement": "Medicare covered as CDx",
    "clinicalAvailability": "FDA-approved IVD kit",
    "totalParticipants": 10000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "FDA-approved companion diagnostic for FLT3-targeted AML therapies. Distributed IVD kit enables in-house testing on ABI genetic analyzers. Essential for quizartinib, midostaurin, and gilteritinib eligibility."
  },
  {
    "id": "tds-kit-12",
    "sampleCategory": "Blood/Plasma",
    "name": "Hedera Profiling 2 ctDNA Test Panel",
    "vendor": "Hedera Dx",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq 2000",
    "approach": "Liquid CGP",
    "method": "Hybrid capture-based NGS covering 32 genes; detects SNVs, indels, CNVs, fusions; reports MSI status. DNA-only workflow optimized for ctDNA with UMI/UDI error correction.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/41015181/",
    "genesAnalyzed": 32,
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "MSI"],
    "cancerTypes": ["Pan-solid tumor", "NSCLC", "Breast", "Colorectal"],
    "targetPopulation": "Advanced solid tumor patients for biomarker-guided therapy selection",
    "indicationsNotes": "Decentralized IVD kit for in-house liquid biopsy testing. Covers >80% of ESCAT Level I genes including ESR1, METex14, and MSI. Requires local validation under CE-IVDR for routine clinical use. Paired with Hedera Prime CE-IVD software for automated OncoKB-powered reporting.",
    "sensitivity": 97,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/41015181/",
    "sensitivityNotes": "96.92% analytical sensitivity for SNVs/Indels at 0.5% VAF in reference standards; 100% fusion sensitivity; 94% concordance for ESCAT Level I variants in 137 clinical samples",
    "specificity": 99.7,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/41015181/",
    "specificityNotes": "99.67% analytical specificity for SNVs/Indels at 0.5% VAF",
    "lod": "0.5% VAF",
    "lodCitations": "https://pubmed.ncbi.nlm.nih.gov/41015181/",
    "lodNotes": "30 ng cfDNA input recommended; 10 ng minimum",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "5 days",
    "fdaStatus": "CE-IVD (software); Performance Studies (panel)",
    "fdaStatusNotes": "Hedera Prime software is CE-IVD registered medical device. Panel labeled for Performance Studies Only - requires local validation under CE-IVDR for clinical use. Not available in US.",
    "reimbursement": "Coverage varies by country",
    "clinicalAvailability": "CE-IVD kit (EU/International)",
    "availableRegions": ["EU", "International"],
    "totalParticipants": 137,
    "totalParticipantsNotes": "International multicenter analytical validation across 10+ centers in 8 countries (France, Germany, Austria, Netherlands, Spain, Italy, Greece, India)",
    "numPublications": 1,
    "technologyDifferentiator": "Decentralized IVD kit for in-house hospital liquid biopsy. Compact 32-gene actionability-focused panel (>80% ESCAT Level I). DNA-only workflow with UMI/UDI error correction. Integrated Hedera Prime CE-IVD software with OncoKB for automated therapy matching. Hedera Comply program supports CE-IVDR local validation."
  },
  {
    "id": "tds-kit-13",
    "sampleCategory": "Blood/Plasma",
    "name": "PGDx elio plasma focus Dx",
    "vendor": "Labcorp/PGDx",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq",
    "approach": "Liquid CGP (kitted IVD)",
    "method": "Qualitative NGS-based IVD using targeted high-throughput hybridization-based capture for cfDNA. Detects SNVs and indels in 33 genes, copy number amplifications (CNAs) in 5 genes (CCND1, CD274, ERBB2, FGFR2, MET), and translocations in 3 genes (ALK, NTRK1, RET). 0.24 Mb panel size, 25 ng cfDNA input, 2x150 bp reads, 30,000x/2,600x total/deduplicated error-corrected coverage.",
    "methodCitations": "https://www.personalgenome.com/products/elio-plasma-focus-dx | https://www.prnewswire.com/news-releases/labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions-302435767.html",
    "genesAnalyzed": 33,
    "genesAnalyzedNotes": "33 genes for SNVs/indels, 5 genes for CNA amplifications (CCND1, CD274, ERBB2, FGFR2, MET), 3 genes for translocations (ALK, NTRK1, RET). Focused panel targeting guideline-recommended biomarkers.",
    "biomarkersReported": ["SNVs", "Indels", "CNAs (amplification)", "Translocations"],
    "cancerTypes": ["Pan-solid tumors"],
    "cancerTypesNotes": "Indicated for use across a wide range of solid tumor types, particularly when tumor tissue is limited or unavailable. Compatible with PGDx elio tissue complete for seamless tissue-to-liquid reflexing workflows.",
    "targetPopulation": "Patients with advanced solid tumors requiring genomic profiling when tumor tissue is unavailable or insufficient",
    "indicationsNotes": "First and only FDA-authorized kitted pan-solid tumor liquid biopsy test. Enables laboratories to retain control over patient specimens and data. As FDA-authorized IVD, requires only on-site verification (not full validation) for rapid implementation.",
    "sensitivity": 96,
    "sensitivityNotes": "Clinical success rate >96% per vendor. High sensitivity across all variant types per FDA De Novo authorization.",
    "sensitivityCitations": "https://www.personalgenome.com/products/elio-plasma-focus-dx",
    "specificity": null,
    "specificityNotes": "FDA De Novo authorization indicates acceptable analytical performance. Specific specificity values not publicly disclosed.",
    "lod": null,
    "lodNotes": "25 ng cfDNA input. Detection sensitivity optimized for actionable variants in advanced solid tumors.",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "4-5 days",
    "tatCitations": "https://www.personalgenome.com/products/elio-plasma-focus-dx",
    "tatNotes": "4-5 days from isolated nucleic acid to variant report. Rapid implementation with on-site verification only (FDA-authorized IVD).",
    "fdaStatus": "FDA De Novo authorized (Aug 2, 2024)",
    "fdaStatusNotes": "First and only FDA-authorized kitted pan-solid tumor liquid biopsy. De Novo classification (DEN240016) enables on-site verification (not full validation) for faster lab implementation. Commercially available since April 23, 2025.",
    "fdaStatusCitations": "https://ir.labcorp.com/news-releases/news-release-details/labcorp-receives-fda-de-novo-marketing-authorization-pgdx-eliotm",
    "fdaApprovalDate": "2024-08-02",
    "reimbursement": "Coverage emerging",
    "reimbursementNote": "FDA-authorized IVD kit. Labs retain sample and data ownership. Reimbursement varies by payer; contact Labcorp for guidance.",
    "clinicalAvailability": "Commercially available (US) since April 2025",
    "availableRegions": ["US"],
    "listPrice": null,
    "listPriceNotes": "Contact Labcorp/PGDx for pricing. Kitted model allows laboratory control over pricing and workflows.",
    "numPublications": 1,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "AACR 2025 presentation on clinical performance. FDA De Novo authorization documentation.",
    "isRUO": false,
    "isInvestigational": false,
    "technologyDifferentiator": "First and only FDA-authorized KITTED pan-solid tumor liquid biopsy. Unlike central lab services, laboratories can run in-house retaining sample and data ownership. Compatible with PGDx elio tissue complete on same instrument for seamless tissue-to-liquid reflexing. Automated bioinformatics reduces manual variant curation burden. Go-live in as few as 6 weeks with streamlined verification process.",
    "dataSourceNotes": "Added December 2025 via LLM Data Review. First FDA-authorized kitted liquid biopsy CGP for pan-solid tumors."
  },
  {
    "id": "tds-kit-14",
    "name": "OncoScreen Focus CDx Tissue Kit",
    "vendor": "Burning Rock Dx (brbiotech)",
    "productType": "Laboratory IVD Kit",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (kitted IVD)",
    "method": "Qualitative NGS-based CE-IVD kit using targeted high-throughput hybridization-based capture for FFPE tissue. Detects SNVs, indels, rearrangements (fusions), and CNVs in 13 genes. Single-Tube-Hybridization, Anti-Contamination-Adapter, and Dual-End-Barcode techniques for rapid, contamination-minimized operation.",
    "methodCitations": "https://us.brbiotech.com/p_details.php?class_id=102101101",
    "genesAnalyzed": 13,
    "genesAnalyzedNotes": "13 genes: EGFR, ALK, ROS1, RET, MET, ERBB2, BRAF, PIK3CA, KRAS, NRAS, HRAS, KIT, PDGFRA. Covers EMA/FDA/NMPA-approved targeted therapy biomarkers.",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions"],
    "cancerTypes": ["NSCLC", "CRC", "GIST"],
    "cancerTypesNotes": "CE-marked CDx for non-small cell lung cancer, colorectal cancer, and gastrointestinal stromal tumor",
    "cancerTypesCitations": "https://us.brbiotech.com/p_details.php?class_id=102101101",
    "sensitivity": 100,
    "sensitivityNotes": "100% accuracy with no missed mutations in 117 clinical samples and commercial references",
    "sensitivityCitations": "https://us.brbiotech.com/p_details.php?class_id=102101101",
    "specificity": 100,
    "specificityNotes": "100% accuracy with no false-positive mutations in 117 clinical samples and commercial references",
    "specificityCitations": "https://us.brbiotech.com/p_details.php?class_id=102101101",
    "smallSampleWarning": true,
    "sampleRequirements": "FFPE tissue; minimum 30ng DNA input",
    "sampleRequirementsNotes": "Low input requirement (30ng) suitable for small samples such as needle biopsies",
    "fdaStatus": "CE-IVD (June 2022)",
    "fdaStatusNotes": "CE-marked June 2022. First NGS-based CDx kit approved by NMPA in China (July 2018) for EGFR/ALK/BRAF/KRAS.",
    "fdaStatusCitations": "https://us.brbiotech.com/details.php?class_id=105107103&id=437",
    "clinicalAvailability": "CE-IVD kit available in Europe and international markets",
    "clinicalAvailabilityNotes": "Compatible with Nexus BR fully automated library preparation system",
    "validationCohortSize": 117,
    "validationCohortStudy": "117 clinical samples and commercial references",
    "isRUO": false,
    "tat": "3-10 business days",
    "tatNotes": "TAT depends on laboratory setup. With Magnis BR/Nexus BR automation: 3 days. Manual workflow: 7-10 days.",
    "tatCitations": "https://www.prnewswire.com/news-releases/burning-rock-dx-launches-magnis-br-to-innovate-total-process-automation-for-ngs-testing-300960507.html",
    "numPublications": 5,
    "numPublicationsNotes": "Burning Rock has 62+ publications in PubMed. OncoScreen Focus CDx-specific publications estimated at 5+.",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/?term=%22Burning+Rock%22+NGS",
    "vendorVerified": false,
    "vendorRequestedChanges": "2025-01-01: Initial submission from Liankai Chi, PhD, Senior Marketing Manager, Burning Rock Dx. Originally rejected as tissue-only; scope expanded to include tissue tests."
  },
  {
    "id": "tds-kit-15",
    "name": "OncoScreen Plus Cancer Mutation Profiling Tissue Kit",
    "vendor": "Burning Rock Dx (brbiotech)",
    "productType": "Laboratory IVD Kit",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (kitted IVD)",
    "method": "Comprehensive NGS-based CE-IVD kit covering 520 cancer-related genes from FFPE tissue. Detects SNVs, indels, CNVs, fusions, and complex biomarkers including TMB, MSI, and HRD. All-in-one solution for immunotherapy and targeted therapy guidance.",
    "methodCitations": "https://www.brbiotech.com/en/p_details.php?class_id=102101102 | https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "genesAnalyzed": 520,
    "genesAnalyzedNotes": "520 NCCN-recommended cancer-related genes spanning 1.64 Mb (312 genes with full exon coverage, 208 with selected regions). Comprehensive coverage for immunotherapy and targeted therapy.",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "HRD"],
    "cancerTypes": ["Pan-solid tumor"],
    "cancerTypesNotes": "Validated across 20 solid tumor types including lung (n=1971), GI (n=625), breast (n=120), gynecological (n=110), genitourinary (n=38)",
    "cancerTypesCitations": "https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "sensitivity": 97,
    "sensitivityPlus": true,
    "sensitivityNotes": "PPA >97% for SNV/INDEL/CNV/Fusion/MSI in 197 clinical samples. Tissue detection rate 97.9% across 3,005 patients.",
    "sensitivityCitations": "https://www.brbiotech.com/en/p_details.php?class_id=102101102 | https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "specificity": 99,
    "specificityPlus": true,
    "specificityNotes": "NPA >99% for SNV/INDEL/CNV/Fusion/MSI. SNV/INDEL NPA >95.8%, Fusion NPA >98.9%, CNV/MSI NPA 100% in 83 benign tumors.",
    "specificityCitations": "https://www.brbiotech.com/en/p_details.php?class_id=102101102",
    "tmb": "Yes",
    "tmbNotes": "TMB calculated from 520-gene panel. Strong correlation with WES-derived TMB (Pearson r=0.845, R²=0.756).",
    "tmbCitations": "https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "msi": "Yes",
    "msiNotes": "MSI status determined from NGS data. MSI-H detected in endometrial (28.6%), CRC (2.5%), ovarian (2.0%), gastric (1.5%), lung adenocarcinoma (0.2%).",
    "msiCitations": "https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "fdaStatus": "CE-IVD (June 2022); Japan MHLW CDx (Sept 2025)",
    "fdaStatusNotes": "CE-marked June 2022. Japan MHLW approved Sept 2025 as CDx for capivasertib (AstraZeneca) - detects PIK3CA, AKT1, PTEN for HR+/HER2- breast cancer.",
    "fdaStatusCitations": "https://us.brbiotech.com/details.php?class_id=105107103&id=437 | https://www.globenewswire.com/news-release/2025/09/24/3155203/0/en/Burning-Rock-s-OncoGuide-OncoScreen-Plus-CDx-System-Now-Approved-in-Japan-as-a-Companion-Diagnostic-for-Capivasertib-in-Breast-Cancer.html",
    "fdaCompanionDxCount": 1,
    "fdaCompanionDxList": ["Capivasertib (Japan MHLW) - PIK3CA/AKT1/PTEN - HR+/HER2- breast cancer"],
    "fdaCompanionDxNotes": "Japan MHLW CDx approval (Sept 2025) via Riken Genesis partnership. OncoGuide OncoScreen Plus CDx System for capivasertib therapy selection.",
    "clinicalAvailability": "CE-IVD kit available in Europe, Japan (CDx), and international markets",
    "clinicalAvailabilityNotes": "Compatible with MGI DNBSEQ-G400 sequencer (Japan). Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR)",
    "clinicalTrials": "L-MOCA study",
    "clinicalTrialsNotes": "Outstanding performance in AstraZeneca's L-MOCA study",
    "totalParticipants": 3005,
    "totalParticipantsNotes": "Concordance study: 3,005 patients across 20 solid tumor types (PMID 35305253)",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Multiple publications including J Pers Med 2022 (PMID 35305253) concordance study, TMB validation studies, and CDx development.",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "validationCohortSize": 197,
    "validationCohortStudy": "197 clinical samples validated against TSO500, ddPCR, Fluorescent PCR-Capillary Electrophoresis, and WES",
    "isRUO": false,
    "tat": "3-10 business days",
    "tatNotes": "TAT depends on laboratory setup. With Magnis BR automation: 3 days. Manual workflow: 7-10 days. Japan CDx via Riken Genesis may have different TAT.",
    "tatCitations": "https://www.prnewswire.com/news-releases/burning-rock-dx-launches-magnis-br-to-innovate-total-process-automation-for-ngs-testing-300960507.html",
    "vendorVerified": false,
    "vendorRequestedChanges": "2025-01-01: Initial submission from Liankai Chi, PhD, Senior Marketing Manager, Burning Rock Dx. Originally rejected as tissue-only; scope expanded to include tissue tests."
  }
]